Next Article in Journal
MGtree: A Fast and Flexible Alignment-Based Metagenomics Pipeline
Previous Article in Journal
Cathepsin C Restricts Influenza A Virus Replication and Is Associated with Suppression of the PI3K-AKT Signaling Pathway
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 18
Issue 6
10.3390/v18060642
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies

by
Tianrong Jia
1,2,
Zehong Huang
1,2,*,
Ningshao Xia
1,2 and
Quan Yuan
1,2,*
1
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen University, Xiamen 361102, China
2
National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen 361102, China
*
Authors to whom correspondence should be addressed.
Viruses 2026, 18(6), 642; https://doi.org/10.3390/v18060642
Submission received: 4 May 2026 / Revised: 31 May 2026 / Accepted: 31 May 2026 / Published: 3 June 2026
(This article belongs to the Section Coronaviruses)
Browse Figures
Review Reports Versions Notes

Abstract

The high-frequency mutation characteristics of SARS-CoV-2 have posed formidable challenges to the development of vaccines and therapeutic agents. Neutralizing antibodies, which serve as effective tools for prevention and control, have undergone continuous updates and iterations in response to viral mutations. This article provides a comprehensive review of researchers’ efforts to achieve both high neutralizing potency and high mutation tolerance in SARS-CoV-2–targeting neutralizing antibodies. Building on the characteristics of conventional antibodies directed against distinct epitopes on the S protein, it further discusses the research on nanobodies, antibody cocktails, multi-specific antibodies, and other antibody formats and engineering approaches, including artificial intelligence–enabled optimization. Each antibody-based strategy targeting SARS-CoV-2 has its own distinctive advantages and potential applications, providing an integrated perspective to support the continued development of antiviral neutralizing antibodies.

1. Introduction

The COVID-19 pandemic has inflicted substantial public health damage worldwide over the past several years. As a key countermeasure beyond vaccines, monoclonal antibodies (mAbs) have demonstrated irreplaceable value in the treatment and prevention of SARS-CoV-2–related disease.
The Spike (S) protein is critical for host cell recognition by SARS-CoV-2 and for initiating the infection process. Viral infection of cells is accomplished through a series of proteolytic cleavages and conformational changes involving multiple domains of the S protein, including the receptor-binding domain (RBD), N-terminal domain (NTD), subdomain 1 (SD1), fusion peptide (FP), and stem helix (SH). This process encompasses a series of biological events, such as host ACE2 binding to the RBD, dissociation of the S1 and S2 subunits, proteolytic cleavage at the S1/S2 and S2′ sites, and conformational changes in the S2 subunit [1,2,3,4]. The S protein is a metastable trimeric glycosylated fusion protein comprising multiple domains; epitopes that are highly accessible, strongly immunogenic, and highly conserved can serve as key targets for the screening and development of neutralizing antibodies (nAb) [5,6,7]. However, the continual emergence of escape variants driven by the high mutability of SARS-CoV-2 has become a major constraint on the clinical efficacy of mAbs.
Accordingly, during the development of nAbs targeting SARS-CoV-2, antibody neutralizing activity, mutational tolerance, and in vivo protective efficacy have become major considerations. Researchers have employed a variety of technical approaches to screen and engineer antibodies with high neutralizing potency and mutational tolerance. The nAbs selected based on the epitope conservatism of the S protein exhibit stronger tolerance to escape mutations. Due to their small molecular size, nanobodies can more readily access cryptic epitopes that are difficult for conventional antibodies to reach. Antibody cocktails broaden the neutralization spectrum of the component antibodies; moreover, rationally designed cocktails may exhibit synergistic enhancement effects that are not present in the individual components. Bi-/multi-specific antibody technologies have also been applied to research on the prevention and treatment of COVID-19. Multi-specific antibodies enable more flexible integration of the strengths of different antibodies; furthermore, conversion into a multi-specific format can introduce new neutralization mechanisms, thereby further enhancing nAb function. Isotype switching, multivalency engineering, and Fc engineering can further optimize antibody functional performance. In addition, artificial intelligence (AI)-based antibody engineering has played an important role in the development of SARS-CoV-2 nAbs from multiple dimensions, including antibody optimization and de novo design.
Here, we provide a comprehensive review of the characteristics and advantages of representative conserved-epitope-based broadly nAbs, nanobodies, antibody cocktails, multispecific antibodies, and AI-engineered antibodies, thereby offering a relatively comprehensive overview of development strategies for antibodies targeting SARS-CoV-2.

2. Broadly Neutralizing Antibodies

2.1. Broadly nAbs Target RBD

The mAbs targeting the SARS-CoV-2 Spike recognize a diverse array of epitopes, covering various domains along the full length of the Spike protein (Figure 1 and Table A1). Among them, the RBD serves as the primary target for nAbs, and multiple approved antibodies are directed against the RBD. However, as one of the regions most enriched in mutational epitopes, nAbs targeting the RBD are also most susceptible to viral escape [8,9]. Based on the epitope location and binding mode of nAbs against the RBD, these antibodies can be further classified into multiple types. Barnes class 1/2 nAbs show a higher frequency of escape mutations at their epitopes, whereas class 3/4 antibodies have relatively more conserved epitopes [10]. Barnes class 1 and 2 antibodies are more readily escaped by the virus; however, benefiting from high epitope immunogenicity, these nAbs are numerically abundant and exhibit high neutralizing activity. Furthermore, epitopes of nAbs targeting the RBD are typically conformational epitopes, and after multiple rounds of screening, broadly nAbs with conserved epitope residues can still be obtained. For instance, the class 1 antibody BA7535 recognizes a conserved epitope on the RBD composed of aa 415/420/421/475/487/489/493, which avoids most mutation hotspots and can effectively neutralize Omicron sublineages such as BA.5, BF.7, XBB.1, XBB.1.5, and EG.5 [11]. Similar class 1 antibodies include 17T2, 87G7, 10-5B, and AZD3152 [12,13,14,15], which require conserved key residues for binding, enabling them to retain neutralizing activity against multiple variants. Among them, AZD3152 has completed Phase III clinical studies and has submitted a marketing authorization application to the European Medicines Agency (EMA) [16]. Some class 1 antibodies can functionally mimic ACE2 in their neutralizing mechanism, causing dissociation of the S1 subunit and disrupting the preS protein conformation. For example, S2K146 has 18 of its 24 epitope residues overlapping with the ACE2 binding site, mimicking ACE2 through electrostatic interactions and shape complementarity. It exhibits neutralizing activity against Omicron BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4/5, XBB.1.5, EG.5.1, and HK.3 [17,18,19,20]. GAR05, ZCP3B4, P2-1B1, P4J15, KXD03, and VIR-7229 [21,22,23,24,25,26] employ similar neutralizing mechanisms to S2K146, and their critical binding residues are also relatively conserved. The class 1 monoclonal antibody BD55-1205, selected through deep mutational scanning (DMS)-based prediction of escape epitopes and also exhibiting ACE2-mimicking characteristics, demonstrates potent broad-spectrum neutralizing activity. It achieves broad neutralization against Omicron HK.3.1, JN.1, and KP.3 via its broad binding to the epitope involving aa 455, 456, 473, and 475 [27]. Another broadly neutralizing class 1 antibody, P5-1C8, maintains neutralizing activity against the Omicron JN.1 despite reduced binding affinity by mediating inter-S protein bridging and inducing aggregation [28]. Class 2 antibody epitopes are prone to mutation and are highly susceptible to escape by new variants. Some class 2 antibodies with conserved key residues at conformational epitopes can maintain neutralizing activity against certain Omicron sublineages, such as P5S-2A9, D1F6, A19-46.1, and COV2-2196 [8,23,29,30].
Class 3 and 4 antibody epitopes are located distant from the ACE2 binding site. The class 3 antibody S309 restricts the RBD from adopting an “up” conformation, and its binding to the S protein creates a spatial barrier that prevents ACE2 binding by obstructing S protein conformational rearrangement [31]. S309 exhibits broad neutralizing activity against variants including Omicron BA.1.1, BA.2, BA.2.75, BA.4/5, BQ.1.1, XBB.1.5, EG.5.1, HK.3, and JN.1 [20,32]. Other broadly nAbs with mechanisms of action similar to S309 include SP1-77 and SW186 [33,34]. The class 3 antibody LY-CoV1404 (bebtelovimab) has an epitope that extends into part of the RBM and exerts neutralizing effects by obstructing ACE2 binding [35]. BA7208, S2X324, P2S-2E9, and 6-2C share binding patterns similar to LY-CoV1404, and all can broadly neutralize multiple Omicron sublineages [14,20,23,32,36,37]. The class 3 antibody 1G11 does not directly interfere with RBD-ACE2 interaction; however, it can induce “head-to-head” aggregation of S protein trimers, creating steric hindrance or occluding the receptor binding site [32]. Among the antibodies mentioned above, both S309 and LY-CoV1404 received FDA EUA but were revoked due to the impact of non-susceptible variants [38,39].
The class 4 antibody CR3022, derived from a SARS-CoV patient, binds to an epitope that does not overlap with the ACE2 binding interface [40]; however, this antibody may exert its biological function by inducing dissociation of S protein trimers [41]. ADG20, Ab246, and DH1047 [30,42,43,44] have epitopes that partially overlap with CR3022 and also belong to the class 4 category; their neutralizing activity against certain variants is reduced. ADG20 completed Phase II/III clinical studies in 2022, but its clinical development was halted due to the impact of immune evasive variants [45]. The class 4 antibody AB2-122, identified via screening in an engineered mouse model, utilizes dual aromatic residues within its HC-CDR3 to recognize a hydrophobic epitope on the Omicron-mutant-remodeled RBD. It achieves broad neutralization against multiple Omicron sublineages (including NB.1.8.1 and XFG) by blocking ACE2 binding [46].
In addition to class 1–4 antibodies, there are also antibodies targeting more cryptic epitopes on the RBD that similarly exhibit potent neutralizing activity and broad specificity. S2H97 binds to a cryptic conserved epitope on the RBD without interfering with ACE2-RBD interaction, and it can induce S protein refolding into a post-fusion state [47], thereby exerting broad-spectrum neutralizing effects against SARS-CoV and SARS-CoV-2 variants including Omicron BA.1, BA.2, XBB.1.5, EG.5.1, HK.3, JN.1, and others [20]. XMA09 and C68 [48,49], which have epitopes similar to that of S2H97, likewise demonstrate significant neutralizing activity against Omicron sublineages and SARS-CoV. GAR12 binds to an epitope located between those of S309 and S2H97, and exhibits neutralizing activity against BA.5 and earlier Omicron sublineages [21]. ION_300 binds to a unique region on another side of the RBM that is occluded by the NTD of adjacent S1 when the RBD is in the “down” conformation [50]; it can effectively neutralize SARS-CoV and SARS-CoV-2 variants BA.2, XBB.1.5, EG.5.1, HK.3, and JN.1 [20] (Figure 1).

2.2. Broadly nAbs Target NTD

Most antibodies targeting the NTD use an antigenic supersite as their epitope, which is located on the periphery of the S protein and represents the largest non-glycosylated surface on the NTD, composed of the N1, N3, and N5 loops. However, this supersite is prone to mutations, with deletions such as aa 69–70del and 144del (Alpha, B.1.1.7), and aa 242–244del and R246I (Beta, B.1.351) all located at the NTD supersite [51,52]. Antibodies of this class include 5–7, C1717, C1520, and C1791 [53,54,55]. Additionally, some NTD nAbs bind to unique epitopes on the N1/N2 loops, competing with ACE2 and blocking S1 shedding; however, insertions or deletions in the N1/N2 loops can cause such antibodies to lose neutralizing activity [56]. If the binding epitope of nAbs targeting the NTD can involve other regions, the breadth of their binding and neutralizing activity may be enhanced. The critical residues of the K501SP6 epitope are aa 122–123, 225, and 163–170; this epitope is relatively conserved in most variants, and its binding involves both the NTD and SD1, forming a cross-domain epitope that can cross-neutralize multiple variants including Omicron BQ.1.1.20, XBB.1, and JN.1 [57]. The C1596, targeting non-antigenic supersites of the NTD, can recognize a quaternary epitope containing the NTD, RBD, and SD1, and can cross-neutralize Omicron XBB.1.5, BA.2.86, and JN.1 [58] (Figure 1).

2.3. Broadly nAbs Target SD1

Several reported nAbs targeting SD1 exhibit broad-spectrum neutralizing effects. S3H3 binds to an epitope on SD1 comprising aa 323–324, 532–537, 554–556, and 581–584 [59]; its neutralizing mechanism may involve inducing a conformational change in the S protein that locks the RBD in a transitional state between “up” and “down” conformations [60]. S3H3 neutralizes Omicron XBB.1, XBB.1.5, EG.5.1, and HK.3 [61,62]. However, the E554 mutation present in BA.2.86 and JN.1 abrogates its neutralizing activity [62,63,64]. P008_60 primarily binds to the L3 loop of SD1 while also interacting with the L4 and L5 loops and the glycan at N331; N-linked glycosylation at N331 significantly reduces its neutralizing activity [65]. Sd1.040 targets SD1 and recognizes an epitope formed by SD1 aa 554–562 and 577–581, as well as RBD aa 520–524. It does not block ACE2 binding but potently inhibits ACE2-induced conformational changes in the S protein, enabling cross-neutralization of variants including Omicron BA.1, BA.2, BA.2.75, BA.2.75.2, and BA.4/5 [66]. The key binding residues for C68.59 are aa 554, 558, 577, 583, and 585. Upon binding SD1, it may trigger a conformational change that indirectly affects RBD-ACE2 interaction and leads to a marked decrease in the structural stability of the S2 subunit [67]. MO11 binds to a conserved epitope on SD1 located adjacent to the N331 glycan, connecting the N-terminal (aa 529–538, 552–555) and C-terminal (aa 322–332, 579–582) segments of SD1. It does not affect S protein binding to ACE2 and broadly neutralizes multiple variants including Omicron BA.1, BA.2, BA.2.75, BA.5, BQ.1.1, XBB.1.5, XBB.1.16, and EG.5.1 [68] (Figure 1).

2.4. Broadly nAbs Target FP

Transmembrane serine protease 2 (TMPRSS2) recognizes the R815 epitope on S2, cleaves the S protein, and exposes the FP, thereby triggering membrane fusion. As a functional epitope essential for viral infection, the FP sequence is relatively conserved and represents one of the ideal targets for broadly nAbs [69]. The mechanism of action for FP-targeting antibodies is relatively uniform; their binding epitopes are typically exposed after ACE2 engages the S protein, and they exert neutralizing effects by hindering S protein cleavage and inhibiting the membrane fusion process. The reported antibodies of this class also exhibit considerable convergence in their binding epitopes. For instance, 76E1, which binds to residues 809–833, exhibits neutralizing activity against both human α- and β-coronaviruses [70]. C20.119, which shares a similar binding epitope, can neutralize BA.1, BA.2, BA.5, BQ.1.1, XBB, XBB.1.5, and SARS-CoV [71]. Antibodies recognizing epitopes within the range of residues 813–825, such as COV44-62, COV44-79, VN01H1, VP12E7, C77G12, fp.006, and fp.007, are capable of effectively neutralizing Omicron sublineages, including BA.1, BA.2, and BA.4/5, among others [66,72,73] (Figure 1).

2.5. Broadly nAbs Target SH

The sequence of the SH epitope is highly conserved; therefore, antibodies targeting SH generally possess promising broad-spectrum potential. Representative antibodies such as S2P6, CV3-25, CC40.8, 7B2, WS6, S2-4D/S2-5D/S2-8D/S2-4A, 1249A8, hr2.016, and CC25.106/CC68.109/CC99.103 primarily recognize overlapping epitopes within the region of residues 1131–1171. They can neutralize early SARS-CoV-2 VOCs, certain Omicron sublineages, and even other coronaviruses such as SARS-CoV, MERS-CoV, and HCoV-OC43 by either blocking conformational transitions or inhibiting virus-host membrane fusion [74,75,76,77,78,79,80,81,82,83,84,85,86]. Among these, some antibodies additionally demonstrate a direct interference with the post-fusion transition. For example, CV3-25 prevents the S protein from adopting a fusion-active state through conformational clash [77], while 1249A8 blocks six-helix bundle formation by “capping” the SH peptide [84]. Furthermore, the SH antibody repertoire derived from IGHV1-46/IGHV3-23 germlines exhibit strong public immunological features. Their critical binding residues, F1148, L1152, and F1156, are highly conserved among β-coronaviruses, forming the structural basis for their broad reactivity [86]. However, despite the conservation of the SH epitope, obtaining potent nAbs remains challenging. Some SH antibodies, such as 28D9, 1.6C7, B6, and IgG22, can bind to the S proteins of multiple coronaviruses but fail to neutralize SARS-CoV-2 due to insufficient affinity or limited epitope accessibility, suggesting that their broad neutralization capacity could be further optimized through affinity maturation in the future [87,88,89] (Figure 1).

2.6. Other nAbs Target S2

Due to issues such as immunogenicity or accessibility, nAbs targeting other epitopes within the S2 subunit are relatively rare. Among them, 3D1 targets a six-amino-acid peptide segment within the heptad repeat 1 (HR1) domain. This epitope is only exposed during the pre-fusion hairpin intermediate state of membrane fusion. 3D1 effectively neutralizes SARS-CoV-2 and SARS-CoV but is evaded by the Omicron Q954H mutation [90]. RAY53 is a nAb targeting the apex of the S2 subunit, spanning the HR1 and central helix (CH) regions. It exhibits weak neutralizing activity against SARS-CoV-2 and MERS-CoV but shows no neutralizing activity against SARS-CoV or Omicron [91]. hMab5.17 targets a highly conserved epitope (aa 1164–1172) and demonstrates neutralizing activity against SARS-CoV and early SARS-CoV-2 VOCs [92].

3. Nanobodies

Nanobodies, primarily derived from the variable domains of camelid heavy-chain-only antibodies (VHHs) or shark immunoglobulin new antigen receptors (VNARs), are single-domain antibodies. They offer advantages such as small molecular size, structural stability, ease of access to cryptic epitopes, and amenability to engineering [93,94], thereby demonstrating unique potential in the development of broadly neutralizing antibodies against coronaviruses. Their primary limitation is a relatively short in vivo half-life; however, constructing multivalent or multispecific antibodies can significantly improve their persistence and enhance their therapeutic potential.
VHHs from camelids represent the minimal antigen-binding unit. Their breadth similarly depends on epitope conservation. However, due to their small size, they can more readily target cryptic epitopes that are difficult for conventional antibodies to access. In some cases, the small molecular format can even enhance neutralizing activity, as seen with VN01H1 and C77G12, whose single-chain variable fragment (scFv) formats outperform their full-length IgG counterparts [73]. Numerous VHHs have demonstrated broad neutralizing capabilities against SARS-CoV-2 variants: for instance, Nanosota-9 and Ma16B06 can bind to RBD in both “up” and “down” conformations and potently neutralize Omicron sublineages [95,96]; 1p1B10, Tnb04-1, Nb1, Nb2, W25, and Nb4 target conserved RBD epitopes and the first four can neutralize variants including Omicron JN.1 [97,98,99,100,101]; 3-2A2-4 exerts broad neutralization by inhibiting the transition of RBD from “down” to “up” [102]; the engineered nanobody C5G2 uses its CDR3 loop to simultaneously engage the RBD and the adjacent NTD, and employs FR2-mediated steric hindrance to inhibit ACE2 binding [103]; IBT-CoV144 neutralizes by crosslinking two S proteins [104]; N235 recognizes a conserved cryptic epitope on the NTD and likely neutralizes multiple Omicron sublineages by interfering with the adjacent RBD and inducing S1 shedding [105]; H17 and H145 target the linear stem-helix (SH) epitope (aa 1139–1152), are effective against Omicron JN.1, KP.3, and SARS-CoV, and retain inhibitory activity even post-fusion as their binding is unaffected by acidic pH [106]. R3DC23 binds to the juxtamembrane region of HR2 (residues 1192–1206), recognizing a quaternary epitope formed by the trimeric HR2 coiled-coil, thereby achieving broad neutralization against SARS-CoV and prevalent SARS-CoV-2 variants [107].
Additionally, shark-derived VNARs constitute another important class of nanobodies. Among these, 79C11 targets a highly conserved region within the S2-HR1 domain, neutralizing SARS-CoV, Omicron JN.1, and KP.2, and can be administered intranasally to prevent XBB infection [108]; the nurse shark-derived S2A9 targets the S2 subunit and exhibits neutralizing activity against Omicron BA.1, BA.2, BA.4/5 [109]. Table 1 summarizes the representative SARS-CoV-2-specific nanobodies discussed above, including their origins, targets, binding affinities, neutralizing activities against Omicron sublineages, and neutralization mechanisms.

4. Antibody Cocktails

Acquiring mAbs that concurrently exhibit high potency and broad neutralizing is challenging, and antibodies targeting a single epitope still face a high risk of viral escape. Consequently, constructing antibody cocktails targeting non-overlapping epitopes has emerged as a key strategy to enhance coverage breadth, reduce escape risk, and achieve synergistic effects. Firstly, cocktails can expand the neutralizing spectrum through complementarity of their components. For example, while individual components of AZD7442 cannot comprehensively cover multiple Omicron sublineages, the combination achieves complementary neutralization [18]. AZD7442 previously received an FDA Emergency Use Authorization (EUA) in 2021. However, in 2024, the EUA for this antibody cocktail was revoked due to the impact of non-susceptible variants [113]. Similarly, the triple-antibody combinations IMM-BCP-01 and EGH rely on component complementarity to broaden their neutralizing range [114,115]. IMM-BCP-01 advanced to Phase I clinical studies in 2022, but its clinical development has since been terminated [116]. Secondly, antibody combinations targeting non-overlapping RBD epitopes can generate significant synergy. For instance, B1-182.1 and A19-46.1 significantly enhance neutralization against Omicron by inducing a triple-RBD-up conformation and “cooperative trapping” [8]; XMA01, XMA04, and XMA09 can form an inter-antibody interaction network on the same RBD to enhance overall binding stability [48]; H014 and HB27 produce an allosteric synergistic effect through conformation induction [117]. Moreover, cocktails targeting non-overlapping epitopes generally possess stronger resistance to viral escape. REGN-COV-2 is less prone to escape compared to competitive or partially competitive combinations [118]; SA55 and SA58 achieve robust, broad-spectrum neutralization against multiple SARS-CoV-2 variants by improving epitope coverage and the genetic barrier to escape [119]; Long-term serial passage experiments also demonstrate the superior resilience of high-coverage, non-overlapping combinations. The combinations 9E12+10D4+2G1 and 7B9-9D11+2G1 showed no breakthrough after 30 passages, whereas the partially overlapping epitope combination 10D4-8G4+2G1 was escaped within just 5 passages [120]. Among the antibodies above, REGN-COV-2 received FDA EUA in 2020, but its authorization was revoked in 2024 due to non-susceptible variants [121]. SA55, as a monotherapy, has entered Phase II clinical studies [122]. Combining antibodies across different S protein subunits, particularly S1 and S2, represents another valuable combinatorial direction. S1 antibodies typically exhibit higher neutralizing potency, while S2 antibodies offer broader coverage due to conserved targets. This pairing enables functional complementation and, under certain conditions, mechanistic synergy. The S2’/FP-targeting antibody 76E1 can be combined with ACE2-binding or ACE2-mimicking RBD antibodies; the latter’s induction of conformational changes in the S protein exposes 76E1’s epitope, thereby enhancing its membrane fusion inhibition [70]. A clear synergy exists between the FP antibody C77G12 and the ACE2-mimicking antibody S2E12, but not with S2M11, which locks the S protein in a closed state, indicating that synergy depends on epitope exposure and conformational transitions [73]. The cocktail composed of 1249A8 (targeting SH) and 1213H7 (targeting RBD) simultaneously blocks distinct key steps in viral entry, demonstrating significant synergistic neutralization against Omicron and superior in vivo efficacy [83]. However, CV3-25 (targeting SH) and CV3-1 (targeting RBD), despite fitting the “dual-blockade” concept, showed no obvious synergy, suggesting that cocktail potentiation depends on functional compatibility and potency balance between components [123].
Beyond neutralizing complementarity, cocktails can integrate Fc effector functions to enhance in vivo protection. For example, combining WRAIR-2125 (targeting RBD) with WRAIR-2039 (targeting NTD) improves in vivo protection [124] and CV3-13 combined with CV3-25 achieves 100% prophylactic protection [125]. The quadruple antibody combination TATX-03b’ not only neutralizes 17 SARS-CoV-2 variants but also significantly activates ADCC- and ADCP-related FcγR signaling in the combined state, demonstrating dual synergy in both neutralization and Fc-mediated functions [126]. Table 2 provides an overview of representative antibody cocktails against SARS-CoV-2, summarizing their components, target epitopes, and in vitro and in vivo synergistic effects.

5. Bi-/Multi-Specific Antibodies

Bi-/multi-specific antibodies integrate multiple antigen-binding modules into a single molecule, enabling the coordinated combination of multiple antiviral mechanisms, including neutralization, conformational regulation, cross-linking/aggregation, and immune effector functions. Specifically, there are multiple integration formats, including Knobs-into-Holes, dual variable domain immunoglobulin (DVD-Ig), cross-over dual variable domain immunoglobulin (CODV-Ig), and single-chain variable fragment (scFv), among others (Figure 2). This integration can enhance neutralizing potency, breadth, and in vivo protective efficacy. Notably, weakly neutralizing or even non-neutralizing parental antibodies can be transformed into highly potent molecules through bi-/multi-specific engineering. For instance, bispecific or mutli-specific antibodies such as G9, Bis3, CoV-X4042, CoV-X2, COVA2-02+LY-CoV1404, 5-HI, Bis1-4, BA7208/7125, and Tri-1/Tri-2 all exhibit superior binding, neutralization, or in vivo protective activity compared to their parental counterparts [36,66,127,128,129,130,131,132,133]. Furthermore, the bispecific nanobody Bn03 and the trispecific antibody 7A9-19B8-S3_29 can further inhibit the virus by inducing S protein conformational changes or trimer dissociation [134,135].
Bi-/multi-specific designs can also effectively utilize parental antibodies whose epitopes overlap, making them difficult to combine in a traditional cocktail. Molecules such as Bi-Nab, bsAb1, Nb1-Nb2/Nb1-Nb2-Fc, and 3F-1B-2A demonstrate that through rational fusion design, competition between antibodies targeting overlapping epitopes can be alleviated, and occupancy and conformational restriction on the RBD or S1 can be enhanced, resulting in neutralization activity superior to that of the parental antibodies or their cocktail [136,137,138,139]. Among these, bsAb1 can sequentially occupy three “up”-conformation RBDs and restrict the dynamic changes of the S protein, highlighting the unique advantages of overlapping epitope antibodies within a multispecific framework [137].
The function of bi-/multi-specific antibodies is highly dependent on their molecular format and structural configuration. The activity can vary significantly when the same parental antibodies are used in different backbones. For example, among bispecific antibodies derived from B38/H4 and H11B11, the IgG-scFv format generally outperforms the DVD-Ig or CrossMab formats [140,141]. The bispecific antibody composed of B38/H4 has advanced to Phase Ia clinical studies [142]. Similarly, bispecific antibodies based on shark VNARs or camelid VHHs show that different heterodimeric or tandem formats involve trade-offs in affinity, neutralization, and ACE2-blocking capacity [143,144]. Beyond the backbone, the order of antigen-binding elements also determines functional output. For instance, in bispecific antibodies constructed from C1596/C952 and 7F3/GW01, the module order can significantly alter neutralizing activity by affecting RBD “up/down” transitions, subsequent antibody binding, and cross-linking capability [58,145]. Similar positional effects are also observed in Bi-Nab, KXD-BsAb02, and the trispecific CODV-Ig 61.1/46.1–182.1 [146,147,148].
In addition to inheriting the direct neutralization mechanisms of their parental antibodies, bi-/multi-specific antibodies often enhance potency through increased cross-linking and aggregation effects. Molecules such as CV1206_521_GS, FD01, BI-2C5B, and 61.1/46.1–182.1 can simultaneously bind multiple S proteins, forming cross-linked complexes or aggregates that significantly enhance viral inhibition [14,148,149,150]. Similarly, 14-H-06 exhibits stronger binding and neutralization than 14-crs-06 due to its ability to cross-link more S proteins [151]. Furthermore, bi-/multi-specific antibodies can be continuously optimized through multimerization or the introduction of additional functional modules. For example, the neutralizing activity of GS4 is further enhanced after trimerization [152]. The Fc-free trimer TNᵀ not only simultaneously blocks all six RBD binding sites on an S trimer but also leverages its DNGR-1 module to promote CD8+ T cell activation, demonstrating the unique potential of bi-/multi-specific platforms for integrated antiviral and immunomodulatory design [153]. Table 3 summarizes the representative bi-/multi-specific antibodies against SARS-CoV-2, including their molecular formats, parental antibodies, target epitopes, and enhanced characteristics relative to parental antibodies and cocktails.

6. Antibody Class Switching and Multivalent Modification

Mucosal immunity serves as the frontline barrier against viral invasion, in which secretory IgA (sIgA) holds unique advantages in preventing infection. Although plasma monomeric IgA typically exhibits lower neutralizing potency against SARS-CoV-2 compared to IgG, dimeric IgA shows an approximately 15-fold average increase in neutralizing activity against the same target [156]. This enhancement is primarily attributed to the ability conferred by the additional antigen-binding site to bridge adjacent S protein trimers and reduce dissociation rates [157]. Correspondingly, the dimeric IgA forms of antibodies such as Cv2.1169, MAb362, ZW2G10, H4, B38, and SA55 IgA1 all demonstrate superior neutralizing activity compared to their monomeric IgA and IgG counterparts [158,159,160,161,162]. Furthermore, the tetravalent secretory IgA bispecific antibody S2-3-IgA2m2, constructed based on aRBD2 and aSA3, exhibits stronger neutralization and better in vivo protection than its bispecific IgG form, and can effectively prevent Omicron BA.5 infection at low doses via intranasal administration [163].
IgG-based engineering represents another approach to enhance antibody efficacy. IgG3, due to its longer and more flexible hinge region, possesses higher bivalent binding efficiency. For example, the IgG3 form of REGN10933 shows over a 100-fold increase in neutralizing activity against the Beta and Omicron compared to its IgG1 form [164].
IgM-based engineering is another important strategy for antibody enhancement. Its advantages include significantly boosting neutralizing activity, reducing effective doses, and conferring additional inhibitory mechanisms such as virion aggregation. The NTD-targeting antibody N235, when engineered into the IgM format (MN235), shows markedly enhanced neutralization and improves intranasal prophylactic efficacy against Omicron BA.1 and XBB by inducing viral aggregation [105]. Similarly, IgM-14 can restore neutralization against IgG-14-resistant viruses and demonstrates superior in vivo protection at low doses [165]. The alpaca nanobody R14, after IgM conversion into MR14, also shows significantly better neutralization against Omicron BA.1, BA.2, and BA.4/5, as well as superior in vivo protection compared to the original molecule. Its mechanism extends beyond ACE2 blockade to include induction of virion aggregation [166].
Beyond engineering modifications mentioned above, multivalent modification is another effective route to enhance antibody potency. Trivalent nanobodies constructed via linkers or trimerization domains, such as Nb4-16t, 79C11-Trimer, and Nb6 Tribody, all exhibit stronger binding, neutralization, and in vivo protective capacity compared to their monovalent forms. The mechanisms primarily involve topological matching with the S protein trimer, simultaneous occupancy of multiple RBDs, and stabilization of specific conformations (e.g., the “3-RBD-down” state) [101,108,167]. Additionally, fusing nanobodies to an IgG Fc can enhance activity by increasing valency, as seen with 79C11, S2A9, W25, saRBD-1, 7F, and Nb12/Nb19 [100,108,109,168,169,170]. Further integration with nanoparticle platforms, such as conjugating 1C4, XMA01/04/09, or B-B2 to mi3 or AaLS particles via SpyTag/SpyCatcher, can further enhance binding stability and neutralizing activity. This is achieved by promoting S protein aggregation, virion cross-linking, increasing steric hindrance, and improving thermal stability, thereby amplifying the antiviral effect [171,172,173].

7. Fc Modification

The antiviral activity of antibodies in vivo is not solely dependent on neutralization; Fc-mediated effector functions can also contribute significantly to protection [174,175]. For example, the non-neutralizing NTD-targeting antibodies CV3-13 and DH1052 show markedly improved protective efficacy after the introduction of Fc-enhancing mutations [125,176]. Similarly, the S2-targeting non-neutralizing antibody COVA2-18, despite lacking neutralizing activity, exhibits prophylactic protection, and experiments have confirmed that this protection relies on intact Fc function [177].
For neutralizing antibodies, Fc function serves as an important complement to their in vivo efficacy. The LALA mutation in CV3-1 significantly impairs its prophylactic and therapeutic effects, while CV3-25 shows enhanced prophylactic activity after GASDALIE engineering [123]. The efficacy of the casirivimab/imdevimab cocktail and S309 also depends on FcR-mediated functions, with the strength of Fc effector activity significantly influencing therapeutic outcomes. However, the contribution of Fc function appears more limited in prophylactic settings, suggesting its role is influenced by the stage of infection and antibody titers [178].
Furthermore, IgG subclass and Fc engineering significantly impact the therapeutic performance of antibody drugs. IgG3, due to its stronger phagocytic and complement-activating capabilities, can further enhance Fc- and complement receptor-mediated phagocytosis when used in a cocktail format, possibly because it more readily forms the hexamers required for C1q activation [179]. However, the impact of Fc function on protection is not universally positive. For instance, the S2-targeting antibody 54043-5, which binds the conserved epitope aa 969–995, lacks neutralizing activity but can mediate ADCP. The wild-type antibody shows no in vivo protection, whereas the LALA-PG mutant version unexpectedly confers protection. This suggests that in some contexts, Fc effector functions might induce excessive inflammation, thereby offsetting their potential benefits [180].
Beyond directly modulating effector functions, Fc engineering can also indirectly enhance in vivo antibody potency by extending serum half-life. For example, both AZD8895 and AZD1061 incorporate the YTE modification to improve their persistence in vivo [181]. Table 4 summarizes representative engineered antibodies against SARS-CoV-2 that incorporate class switching, multivalent modification, or Fc engineering, highlighting the specific engineering strategies and their functional advantages.

8. Artificial Intelligence-Based Design and Optimization

With the advancement of AI, the potential of this emerging technology in the design and optimization of mAbs has gradually become apparent. In the context of COVID-19 antibody-related research and development, AI has also demonstrated unique advantages over conventional development approaches. In the field of de novo antibody design, the team at Vanderbilt University Medical Center proposed a sequence-based protein language model (PLM) termed MAGE (monoclonal antibody generator) for the de novo generation of SARS-CoV-2 RBD-specific antibodies. Wet-lab validation of 20 generated antibodies revealed that 45% achieved positive antigen binding, and some monoclonal antibodies exhibited KD values against the RBD at the nanomolar to sub-nanomolar level; among these, monoclonal antibodies RBD-409 and RBD-951 demonstrated broad-spectrum neutralizing potency spanning wild-type, Omicron BA.2, BJ.1, and BA.2.87.1 [185].
In the field of antibody optimization, Lawrence Livermore National Laboratory proposed a computational approach termed GUIDE (generative unconstrained intelligent drug engineering) that, under zero-shot conditions, achieved the restoration of COV2-2130’s neutralizing potency against Omicron within only three weeks. The best-performing antibody design, 2130-1-0114-112, carried only four amino acid substitutions, yet its IC50 values against Omicron BA.1 and BA.4 were improved by two orders of magnitude compared to the parental antibody [186]. Another study led by a team at Stanford University demonstrated, from an AI agent perspective, the potential of large language models (LLMs) in antibody optimization. This study employed GPT-4o to construct a virtual lab comprising an immunologist, a machine learning expert, a computational biologist, and a scientific critic. Through the introduction of point mutations, four existing nanobodies against the wild-type strain (Ty1, H11-D4, Nb21, and VHH-72) were optimized to enhance their binding affinity against Omicron KP.3. Some of the optimized antibodies showed improved binding to the wild-type and Omicron JN.1; however, few directly enhanced binding potency against the target Omicron KP.3 [187].
Overall, AI-based antibody design and optimization have yet to converge on a unified and effective research paradigm; nevertheless, multiple studies have provided preliminary evidence of their advantages over conventional wet-lab-based rational design approaches. With further iterative development in the future, AI-based antibody optimization and design may eventually achieve methodological maturity and serve as a viable replacement for traditional approaches.

9. Conclusions

The high mutability of SARS-CoV-2 has driven continuous iterative advancement in antibody technologies. Broadly neutralizing antibodies, nanobodies, antibody cocktails, bi-/multi-specific antibodies, and AI-driven antibody design and optimization have emerged as core innovation directions, each leveraging distinct advantages to overcome the limitations of conventional antibody approaches. These technologies collectively drive structural optimization and functional innovation in antibodies from multiple perspectives, and hold promise for addressing key challenges in anti-SARS-CoV-2 and pan-coronavirus antibody development, including insufficient neutralizing potency, low tolerance to escape mutations, and suboptimal in vivo protective efficacy. With the deep integration of genetic engineering, structural biology, and artificial intelligence, future antiviral antibody research and development will advance toward greater efficacy, broader spectrum coverage, and enhanced accessibility, thereby providing more robust technological support for global pandemic prevention and control, as well as preparedness against future “Disease X”.

Author Contributions

Conceptualization, T.J., Z.H. and Q.Y.; writing original draft preparation, T.J. and Z.H.; writing review and editing, Z.H. and Q.Y.; visualization, T.J.; supervision, N.X. and Q.Y.; funding acquisition, Z.H. and Q.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (824B2066, 92369110, 82272305).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

The following abbreviations are used in this manuscript:
mAbMonoclonal antibody
nAbNeutralizing antibody
RBDReceptor-binding domain
NTDN-terminal domain
SD1Subdomain 1
FPFusion peptide
SHStem helix
TMPRSS2Transmembrane serine protease 2
AIArtificial intelligence

Appendix A

Table A1. Representative SARS-CoV-2 broadly neutralizing antibodies and their neutralizing activity against Omicron sublineages.
Table A1. Representative SARS-CoV-2 broadly neutralizing antibodies and their neutralizing activity against Omicron sublineages.
NameTargetNeutralizing Activity Against Omicron Sublineages (IC50)
BA7535 [11]RBD class 1BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.13, BA.2.38.1, BA.2.74, BA.2.75, BA.2.76, BA.2.77, BA.2.79, BA.2.80, BA.3, BA.4/5, BA.4.6, BA.4.7, BA.5.5.1, BF.7, BQ.1, BQ.1.1, XBB.1, XBB.1.5, XBB.1.9.1, CH.1.1, EG.5 (0.3789–274.4 ng/mL)
17T2 [12]RBD class 1BA.1, BA.2, BA.4/5, BQ.1.1, XBB.1.5, XBB.1.16, EG.5.1, BA.2.86 (3.2–1180 ng/mL)
87G7 [13]RBD class 1BA.1, BA.2 (6.7–10.2 ng/mL)
10-5B [14]RBD class 1BA.1, BA.2, BA.2.12.1, BA.2.75, BN.1, BA.3, XD (4–16 ng/mL)
AZD3152 [15]RBD class 1BA.1, BA.1.1, BA.2, BA.2.12.1, BA.4/5, BA.2.75, BA.4.6, BA.4.7, BA.5.9, BA.2.75.2, BF.7, BQ.1, BQ.1.1, XBB, XBB.1, XBB.1.5, XBB.1.16, BA.2.86, JN.1, XBB.1.5.10, EG.5.1, HV.1, HK.3 (3.2–2286.2 ng/mL)
S2K146 [17,18,19,20]RBD class 1BA.1, BA.1.1, BA.2, BA.3, BA.2.13, BA.2.12.1, BA.4/5, XBB.1.5, EG.5.1, HK.3 (11–4147 ng/mL)
GAR05 [21]RBD class 1BA.1, BA.2, BA.5 (71.31–337.6 ng/mL)
ZCP3B4 [22]RBD class 1BA.1, BA.2, BA.2.12.1, BA.2.75, BA.4/5, BF.7, BE.1.1, BQ.1.1, XBB, XBB.1, XBB.1.5, HK.3, HV.1, EG.5.1, BA.2.86, JN.1, KP.2 (2.7–9.8 ng/mL)
P2-1B1 [23]RBD class 1BA.1, BA.2, BA.2.12.1, BA.2.75, BA.3, BA.4/5 (7.6–1619.2 ng/mL)
P4J15 [24]RBD class 1BA.1, BA.4/5, BA.2.75.2, BQ.1, BQ.1.1, XBB.1, XBB.1.5, CH.1.1, XBB.1.16, XBB.1.16.1, XBB.2.3, EG.1, EG.5.1 (2–18 ng/mL)
KXD03 [25]RBD class 1BA.1, BA.2, BA.3, BA.4/5, BA.2.75, BF.7, BQ.1, XBB, XBB.1, XBB.1.5, XBB.1.16, EG.5, EG.5.1, FL.1.5, FL.1.5.1, HK.3 (22–489 ng/mL)
VIR-7229 [26]RBD class 1BA.1, BA.2, BA.2.3, BA.2.75.2, BA.5, BQ.1.1, XBB.1.5, CH.1.1, XBB.2.3, EG.5, EG.5.1, XBB.1.16, XBB.1.16.1, XBB.1.16.6, FL.1.5.1, HV.1, XBB.1.5.70, HK.3, JD.1.1, BA.2.86, JN.1, JN.1.16, JN.1.18, BA.2.87.1 (1.34–434.5 ng/mL)
BD55-1205 [27]RBD class 1BA.1, BA.2, BA.5, BQ.1.1, XBB.1.5, HK.3.1, JN.1, KP.3 (3–12 ng/mL)
P5-1C8 [23,28]RBD class 1BA.1, BA.2, BA.2.12.1, BA.2.75, BA.3, BA.4/5, JN.1 (7.7–21 ng/mL)
P5S-2A9 [23]RBD class 2BA.1, BA.2, BA.2.12.1, BA.2.75, BA.3, BA.4/5 (13.4–1102.4 ng/mL)
D1F6 [29]RBD class 2BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.13, BA.3, BA.4/5, BQ.1.1, XBB.1.5 (15–5038 ng/mL)
A19-46.1 [8]RBD class 2BA.1 (223 ng/mL)
COV2-2196 [8,30]RBD class 2BA.1, BA.1.1, BA.2, BA.2.12.1 (361–704 ng/mL)
S309 [20,32]RBD class 3BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.4/5, BF.7, BQ.1, BQ.1.1, XBB, XBB.1.5, EG.5.1, HK.3, BA.2.86, JN.1 (252.7–11,742 ng/mL)
SP1-77 [33]RBD class 3BA.1, BA.2, BA.3, BA.4/5, BA.2.12.1 (6.5–33 ng/mL)
SW186 [34]RBD class 3BA.1 (332 ng/mL)
LY-CoV1404 [20,35,130]RBD class 3BA.1, BA.2, BA.4/5, BQ.1.1 (0.4–27 ng/mL)
BA7208 [36]RBD class 3BA.1, BA.2, BA.2.12.1, BA.2.13, BA.3, BA.4/5 (1.24–5.52 ng/mL)
S2X324 [37]RBD class 3BA.1, BA.2, BA.4-V3G, BA.5, BA.2.12.1 (49.8–2650.7 ng/mL)
P2S-2E9 [23]RBD class 3BA.1, BA.2, BA.2.12.1, BA.2.75, BA.3, BA.4/5 (8.1–3129.2 ng/mL)
6-2C [14]RBD class 3BA.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BN.1, BA.3, BA.4, BA.4.6, BA.5, BF.7, BQ.1, BQ.1.1, XD, XBB, XBB.1.5 (194–3584 ng/mL)
1G1 [32]RBD class 3BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.4/5 (1.2–19.6 ng/mL)
ADG20 [14,30,42]RBD class 4BA.1, BA.1.1, XD (181–1203 ng/mL)
DH1047 [30,44]RBD class 4BA.1, BA.1.1 (4322–5723 ng/mL)
AB2-122 [46]RBD class 4BA.1, BA.2, BA.3, BA.5, BQ.1.1, XBB.1.5, BA.2.86, JN.1, KP.2, KP.3, KP.3.1.1, LP.8.1.1, MC.10.1, NB.1.8.1, XFG (20–1170 ng/mL)
S2H97 [20,47,49]RBD othersBA.1, BA.2, BA.5, BQ.1.1, XBB.1.5, EG.5.1, HK.3, BA.2.86, JN.1 (224–1539 ng/mL)
C68.61 [49,67]RBD othersBA.1, BA.2, BA.2.12.1, XBB, XBB.4, XBB.1.5, BA.4/5, BQ.1.1, EG.5.1, JN.1 (120–850 ng/mL)
GAR12 [21]RBD othersBA.1, BA.2, BA.5 (16.17–62.59 ng/mL)
ION_300 [20,50]RBD othersBA.2, XBB.1.5, EG.5.1, HK.3, BA.2.86, JN.1 (343–3838 ng/mL)
5–7 [54]NTD supersiteBA.1, BA.1.1, BA.3 (100–1000 ng/mL, Inferred from the neutralization curve)
C1717 [55]NTD supersiteBA.1 (507 ng/mL)
C1520 [55]NTD supersiteBA.1 (31 ng/mL)
C1791 [55]NTD supersiteBA.1 (167 ng/mL)
BD58-0706 [56]NTD N1/N2 loopsBA.2, BA.2.75, BA.5, BQ.1.1, XBB, XBB.1, XBB.1.5, EG.5.1, HK.3.1 (1–35 ng/mL)
K501SP6 [57]NTD close to SD1BA.1, BA.2, BA.5, BQ.1.1.20, XBB.1, BA.2.86, JN.1 (3.06–25.9 μg/mL)
C1596 [58]quaternary epitope containing the NTD, RBD and SD1BA.1, BA.4/5, XBB.1.5, EG.5.1, BA.2.86, JN.1 (57–4450 ng/mL)
S3H3 [59,60,61,62,63]SD1BA.1, BA.2, XBB.1, XBB.1.5, EG.5.1, HK.3 (24–41 ng/mL)
SD1-1 [64]SD1BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.4/5, BA.4.6, BA.2.75.2, BA.2.3.20, BA.2.10.4, BQ.1, BQ.1.1, BS.1, BF.7, BJ.1, BN.1, CH.1.1, CA.3.1, XBB, XBB.1, XBB.1.5, XBB.1.5.10, XBB.1.5.70 (12–66 ng/mL)
P008_60 [65]SD1BA.1 (10–100 μg/mL, Inferred from the neutralization curve)
Sd1.040 [66]SD1BA.1, BA.2, BA.2.75, BA.2.75.2, BA.4/5 (1004–4486 ng/mL)
C68.59 [67]SD1BA.1, BA.2, BA.2.12.1, XBB, XBB.4, XBB.1.5, BA.4/5, BQ.1.1 (34–156 ng/mL)
MO11 [68]SD1BA.1, BA.2, BA.2.75, BA.5, BQ.1.1, XBB.1, XBB.1.5, XBB.1.16, EG.5.1 (110.3–467.6 ng/mL)
76E1 [70]FPBA.1 (100 ng/mL, Inferred from the neutralization curve)
C20.119 [71]FPBA.1, BA.2, BA.5, BQ.1.1, XBB, XBB.1.5 (19–59 μg/mL)
COV44-62 [72]FPBA.1, BA.2, BA.4/5 (10.38–51.89 μg/mL)
COV44-79 [72]FPBA.1, BA.2, BA.4/5 (33.02–55.44 μg/mL)
VN01H1 [73]FPBA.1, BA.2 (12.5–19.7 μg/mL)
VP12E7 [73]FPNA
C77G12 [73]FPBA.1, BA.2 (2.9–5.4 μg/mL)
fp.007 [66]FPBA.1, BA.2, BA.2.75, BA.2.75.2, BA.4/5 (1889–14,469 ng/mL)
S2P6 [66,74]SHBA.1, BA.2, BA.2.75, BA.2.75.2, BA.4/5 (29,351–68,964 ng/mL)
CV3-25 [66,75,76]SHBA.1, BA.2, BA.2.75, BA.2.75.2, BA.4/5 (571.9–2469 ng/mL)
CC40.8 [79,85]SHNA
WS6 [81]SHBA.1 (3.43 μg/mL)
1249A8 [83]SHNA
hr2.016 [66]SHBA.1, BA.2, BA.2.75, BA.2.75.2, BA.4/5 (453.6–1082 ng/mL)
CC99.103 [85]SHBA.1, BA.2, XBB, BA.2.12.1, BA.2.75, BA.2.75.2, BA.4/5, BA.4.6, BQ.1.1 (1.4–20 μg/mL)
NA, not available.

References

  1. Essalmani, R.; Jain, J.; Susan-Resiga, D.; Andréo, U.; Evagelidis, A.; Derbali, R.M.; Huynh, D.N.; Dallaire, F.; Laporte, M.; Delpal, A.; et al. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity. J. Virol. 2022, 96, e0012822. [Google Scholar] [CrossRef]
  2. Akıl, C.; Xu, J.; Shen, J.; Zhang, P. Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET. Nat. Commun. 2025, 16, 5150. [Google Scholar] [CrossRef] [PubMed]
  3. Grunst, M.W.; Qin, Z.; Dodero-Rojas, E.; Ding, S.; Prévost, J.; Chen, Y.; Hu, Y.; Pazgier, M.; Wu, S.; Xie, X.; et al. Structure and inhibition of SARS-CoV-2 spike refolding in membranes. Science 2024, 385, 757–765. [Google Scholar] [CrossRef] [PubMed]
  4. Chen, B.; Farzan, M.; Choe, H. SARS-CoV-2 spike protein: Structure, viral entry and variants. Nat. Rev. Microbiol. 2025, 23, 455–468. [Google Scholar] [CrossRef] [PubMed]
  5. Shi, W.; Cai, Y.; Zhu, H.; Peng, H.; Voyer, J.; Rits-Volloch, S.; Cao, H.; Mayer, M.L.; Song, K.; Xu, C.; et al. Cryo-EM structure of SARS-CoV-2 postfusion spike in membrane. Nature 2023, 619, 403–409. [Google Scholar] [CrossRef]
  6. Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020, 367, 1260–1263. [Google Scholar] [CrossRef]
  7. Cai, Y.; Zhang, J.; Xiao, T.; Peng, H.; Sterling, S.M.; Walsh, R.M.; Rawson, S.; Rits-Volloch, S.; Chen, B. Distinct conformational states of SARS-CoV-2 spike protein. Science 2020, 369, 1586–1592. [Google Scholar] [CrossRef]
  8. Zhou, T.; Wang, L.; Misasi, J.; Pegu, A.; Zhang, Y.; Harris, D.R.; Olia, A.S.; Talana, C.A.; Yang, E.S.; Chen, M.; et al. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science 2022, 376, eabn8897. [Google Scholar] [CrossRef]
  9. Ji, Y.; Zhang, Q.; Cheng, L.; Ge, J.; Wang, R.; Fang, M.; Mucker, E.M.; Chen, P.; Ma, J.; Zhang, R.; et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front. Immunol. 2022, 13, 980435. [Google Scholar] [CrossRef]
  10. Barnes, C.O.; Jette, C.A.; Abernathy, M.E.; Dam, K.-M.A.; Esswein, S.R.; Gristick, H.B.; Malyutin, A.G.; Sharaf, N.G.; Huey-Tubman, K.E.; Lee, Y.E.; et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 2020, 588, 682–687. [Google Scholar] [CrossRef] [PubMed]
  11. Wang, Y.; Yan, A.; Song, D.; Duan, M.; Dong, C.; Chen, J.; Jiang, Z.; Gao, Y.; Rao, M.; Feng, J.; et al. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants. Nat. Commun. 2024, 15, 842. [Google Scholar] [CrossRef]
  12. de Campos-Mata, L.; Trinité, B.; Modrego, A.; Tejedor Vaquero, S.; Pradenas, E.; Pons-Grífols, A.; Rodrigo Melero, N.; Carlero, D.; Marfil, S.; Santiago, C.; et al. A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity. Nat. Commun. 2024, 15, 1051. [Google Scholar] [CrossRef]
  13. Du, W.; Hurdiss, D.L.; Drabek, D.; Mykytyn, A.Z.; Kaiser, F.K.; González-Hernández, M.; Muñoz-Santos, D.; Lamers, M.M.; van Haperen, R.; Li, W.; et al. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. Sci. Immunol. 2022, 7, eabp9312. [Google Scholar] [CrossRef] [PubMed]
  14. Liu, Y.; Wang, Z.; Zhuang, X.; Zhang, S.; Chen, Z.; Zou, Y.; Sheng, J.; Li, T.; Tai, W.; Yu, J.; et al. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nat. Commun. 2023, 14, 2179. [Google Scholar] [CrossRef]
  15. Cai, Y.; Diallo, S.; Rosenthal, K.; Ren, K.; Flores, D.J.; Dippel, A.; Oganesyan, V.; van Dyk, N.; Chen, X.; Cantu, E.; et al. AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults. Sci. Transl. Med. 2024, 16, eado2817. [Google Scholar] [CrossRef] [PubMed]
  16. AstraZeneca. Sipavibart EMA Regulatory Submission Accepted Under Accelerated Assessment for COVID-19 Prevention. Available online: https://www.astrazeneca.com/media-centre/press-releases/2024/sipavibart-ema-regulatory-submission-accepted-under-accelerated-assessment-for-covid-19-prevention.html (accessed on 28 May 2026).
  17. Park, Y.J.; De Marco, A.; Starr, T.N.; Liu, Z.; Pinto, D.; Walls, A.C.; Zatta, F.; Zepeda, S.K.; Bowen, J.E.; Sprouse, K.R.; et al. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science 2022, 375, 449–454. [Google Scholar] [CrossRef]
  18. Cao, Y.; Yisimayi, A.; Jian, F.; Song, W.; Xiao, T.; Wang, L.; Du, S.; Wang, J.; Li, Q.; Chen, X.; et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022, 608, 593–602. [Google Scholar] [CrossRef]
  19. Cameroni, E.; Bowen, J.E.; Rosen, L.E.; Saliba, C.; Zepeda, S.K.; Culap, K.; Pinto, D.; VanBlargan, L.A.; De Marco, A.; di Iulio, J.; et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 2022, 602, 664–670. [Google Scholar] [CrossRef]
  20. Yang, H.; Guo, H.; Wang, A.; Cao, L.; Fan, Q.; Jiang, J.; Wang, M.; Lin, L.; Ge, X.; Wang, H.; et al. Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants. Nat. Commun. 2024, 15, 7715. [Google Scholar] [CrossRef]
  21. Rouet, R.; Henry, J.Y.; Johansen, M.D.; Sobti, M.; Balachandran, H.; Langley, D.B.; Walker, G.J.; Lenthall, H.; Jackson, J.; Ubiparipovic, S.; et al. Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients. Nat. Commun. 2023, 14, 687. [Google Scholar] [CrossRef] [PubMed]
  22. Luo, M.; Zhou, R.; Tang, B.; Liu, H.; Chen, B.; Liu, N.; Mo, Y.; Zhang, P.; Lee, Y.L.; Ip, J.D.; et al. Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants. eBioMedicine 2024, 108, 105354. [Google Scholar] [CrossRef]
  23. Ju, B.; Zhang, Q.; Wang, Z.; Aw, Z.Q.; Chen, P.; Zhou, B.; Wang, R.; Ge, X.; Lv, Q.; Cheng, L.; et al. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. Nat. Immunol. 2023, 24, 690–699. [Google Scholar] [CrossRef]
  24. Fenwick, C.; Turelli, P.; Duhoo, Y.; Lau, K.; Herate, C.; Marlin, R.; Lamrayah, M.; Campos, J.; Esteves-Leuenberger, L.; Farina, A.; et al. Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys. J. Infect. 2023, 87, 524–537. [Google Scholar] [CrossRef]
  25. Li, L.; Chen, X.; Wang, Z.; Li, Y.; Wang, C.; Jiang, L.; Zuo, T. Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages. PLoS Pathog. 2023, 19, e1011856. [Google Scholar] [CrossRef]
  26. Rosen, L.E.; Tortorici, M.A.; De Marco, A.; Pinto, D.; Foreman, W.B.; Taylor, A.L.; Park, Y.-J.; Bohan, D.; Rietz, T.; Errico, J.M.; et al. A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification. Cell 2024, 187, 7196–7213.e7126. [Google Scholar] [CrossRef]
  27. Jian, F.; Wec, A.Z.; Feng, L.; Yu, Y.; Wang, L.; Wang, P.; Yu, L.; Wang, J.; Hou, J.; Berrueta, D.M.; et al. Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants. Nat. Microbiol. 2025, 10, 2003–2017. [Google Scholar] [CrossRef]
  28. Lv, N.; Chen, P.; Dai, X.; Xu, H.; Li, Z.; Shan, Z.; Li, J.; Guo, F.; Chen, Y.; Li, J.; et al. IgG-Bridging-Seeded Synergistic Aggregation of SARS-CoV-2 Spikes Underlies Potent Neutralization by a Low-Affinity Antibody. Adv. Sci. 2026, 13, e17192. [Google Scholar] [CrossRef] [PubMed]
  29. Liu, B.; Niu, X.; Deng, Y.; Zhang, Z.; Wang, Y.; Gao, X.; Liang, H.; Li, Z.; Wang, Q.; Cheng, Y.; et al. An unconventional VH1-2 antibody tolerates escape mutations and shows an antigenic hotspot on SARS-CoV-2 spike. Cell Rep. 2024, 43, 114265. [Google Scholar] [CrossRef] [PubMed]
  30. Wang, Q.; Guo, Y.; Iketani, S.; Nair, M.S.; Li, Z.; Mohri, H.; Wang, M.; Yu, J.; Bowen, A.D.; Chang, J.Y.; et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022, 608, 603–608. [Google Scholar] [CrossRef] [PubMed]
  31. Pinto, D.; Park, Y.J.; Beltramello, M.; Walls, A.C.; Tortorici, M.A.; Bianchi, S.; Jaconi, S.; Culap, K.; Zatta, F.; De Marco, A.; et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 2020, 583, 290–295. [Google Scholar] [CrossRef]
  32. Sun, H.; Wang, Y.; Chen, X.; Jiang, Y.; Wang, S.; Huang, Y.; Liu, L.; Li, Y.; Lan, M.; Guo, H.; et al. Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant. J. Virol. 2023, 97, e01137-23. [Google Scholar] [CrossRef] [PubMed]
  33. Luo, S.; Zhang, J.; Kreutzberger, A.J.B.; Eaton, A.; Edwards, R.J.; Jing, C.; Dai, H.-Q.; Sempowski, G.D.; Cronin, K.; Parks, R.; et al. An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion. Sci. Immunol. 2022, 7, eadd5446. [Google Scholar] [CrossRef] [PubMed]
  34. Fang, Y.; Sun, P.; Xie, X.; Du, M.; Du, F.; Ye, J.; Kalveram, B.K.; Plante, J.A.; Plante, K.S.; Li, B.; et al. An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif. Sci. Immunol. 2022, 7, eabp9962. [Google Scholar] [CrossRef]
  35. Westendorf, K.; Žentelis, S.; Wang, L.; Foster, D.; Vaillancourt, P.; Wiggin, M.; Lovett, E.; van der Lee, R.; Hendle, J.; Pustilnik, A.; et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022, 39, 110812. [Google Scholar] [CrossRef]
  36. Wang, Y.; Yan, A.; Song, D.; Dong, C.; Rao, M.; Gao, Y.; Qi, R.; Ma, X.; Wang, Q.; Xu, H.; et al. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. Cell Discov. 2023, 9, 3. [Google Scholar] [CrossRef]
  37. Park, Y.J.; Pinto, D.; Walls, A.C.; Liu, Z.; De Marco, A.; Benigni, F.; Zatta, F.; Silacci-Fregni, C.; Bassi, J.; Sprouse, K.R.; et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 2022, 378, 619–627. [Google Scholar] [CrossRef] [PubMed]
  38. U.S. Food and Drug Administration. Frequently Asked Questions on the Emergency Use Authorization of Sotrovimab. Available online: https://www.fda.gov/media/149535/download (accessed on 28 May 2026).
  39. U.S. Food and Drug Administration. Frequently Asked Questions on the Emergency Use Authorization of Bebtelovimab for the Treatment of COVID-19. Available online: https://www.fda.gov/media/156154/download (accessed on 28 May 2026).
  40. Yuan, M.; Wu, N.C.; Zhu, X.; Lee, C.D.; So, R.T.Y.; Lv, H.; Mok, C.K.P.; Wilson, I.A. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 2020, 368, 630–633. [Google Scholar] [CrossRef]
  41. Huo, J.; Zhao, Y.; Ren, J.; Zhou, D.; Duyvesteyn, H.M.E.; Ginn, H.M.; Carrique, L.; Malinauskas, T.; Ruza, R.R.; Shah, P.N.M.; et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host Microbe 2020, 28, 445–454.e446. [Google Scholar] [CrossRef]
  42. Yuan, M.; Zhu, X.; He, W.T.; Zhou, P.; Kaku, C.I.; Capozzola, T.; Zhu, C.Y.; Yu, X.; Liu, H.; Yu, W.; et al. A broad and potent neutralization epitope in SARS-related coronaviruses. Proc. Natl. Acad. Sci. USA 2022, 119, e2205784119. [Google Scholar] [CrossRef]
  43. Sankhala, R.S.; Dussupt, V.; Chen, W.-H.; Bai, H.; Martinez, E.J.; Jensen, J.L.; Rees, P.A.; Hajduczki, A.; Chang, W.C.; Choe, M.; et al. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain. Structure 2024, 32, 131–147.e137. [Google Scholar] [CrossRef]
  44. Martinez, D.R.; Schäfer, A.; Gobeil, S.; Li, D.; De la Cruz, G.; Parks, R.; Lu, X.; Barr, M.; Stalls, V.; Janowska, K.; et al. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Sci. Transl. Med. 2022, 14, eabj7125. [Google Scholar] [CrossRef] [PubMed]
  45. ClinicalTrials. Evaluation of ADG20 for the Prevention of COVID-19 (EVADE). Available online: https://clinicaltrials.gov/study/NCT04859517?intr=ADG20&viewType=Card&rank=1 (accessed on 28 May 2026).
  46. Batra, H.; Luo, S.; Saunders, K.O.; Higgins, J.S.; Jian, F.; Zhang, J.; Kibria, M.G.; Jonaid, G.M.; Zhou, Q.J.; Eaton, A.; et al. Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human VH1-2-rearranging mouse models. Proc. Natl. Acad. Sci. USA 2026, 123, e2537053123. [Google Scholar] [CrossRef]
  47. Starr, T.N.; Czudnochowski, N.; Liu, Z.; Zatta, F.; Park, Y.J.; Addetia, A.; Pinto, D.; Beltramello, M.; Hernandez, P.; Greaney, A.J.; et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 2021, 597, 97–102. [Google Scholar] [CrossRef]
  48. Wang, S.; Sun, H.; Zhang, Y.; Yuan, L.; Wang, Y.; Zhang, T.; Wang, S.; Zhang, J.; Yu, H.; Xiong, H.; et al. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. Cell Rep. 2022, 39, 110862. [Google Scholar] [CrossRef]
  49. Ruiz, F.; Foreman, W.B.; Lilly, M.; Baharani, V.A.; Depierreux, D.M.; Chohan, V.; Taylor, A.L.; Guenthoer, J.; Ralph, D.; Matsen Iv, F.A.; et al. Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses. PLoS Pathog. 2024, 20, e1012650. [Google Scholar] [CrossRef]
  50. Bullen, G.; Galson, J.D.; Hall, G.; Villar, P.; Moreels, L.; Ledsgaard, L.; Mattiuzzo, G.; Bentley, E.M.; Masters, E.W.; Tang, D.; et al. Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses. Front. Immunol. 2021, 12, 678570. [Google Scholar] [CrossRef]
  51. Cerutti, G.; Guo, Y.; Zhou, T.; Gorman, J.; Lee, M.; Rapp, M.; Reddem, E.R.; Yu, J.; Bahna, F.; Bimela, J.; et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 2021, 29, 819–833.e817. [Google Scholar] [CrossRef]
  52. Lok, S.M. An NTD supersite of attack. Cell Host Microbe 2021, 29, 744–746. [Google Scholar] [CrossRef] [PubMed]
  53. Cerutti, G.; Guo, Y.; Wang, P.; Nair, M.S.; Wang, M.; Huang, Y.; Yu, J.; Liu, L.; Katsamba, P.S.; Bahna, F.; et al. Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. Cell Rep. 2021, 37, 109928. [Google Scholar] [CrossRef] [PubMed]
  54. Ai, J.; Wang, X.; He, X.; Zhao, X.; Zhang, Y.; Jiang, Y.; Li, M.; Cui, Y.; Chen, Y.; Qiao, R.; et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe 2022, 30, 1077–1083.e1074. [Google Scholar] [CrossRef]
  55. Wang, Z.; Muecksch, F.; Cho, A.; Gaebler, C.; Hoffmann, H.H.; Ramos, V.; Zong, S.; Cipolla, M.; Johnson, B.; Schmidt, F.; et al. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-CoV-2 spike proteins. Immunity 2022, 55, 998–1012.e1018. [Google Scholar] [CrossRef] [PubMed]
  56. Niu, X.; Li, Z.; Wang, J.; Jian, F.; Yu, Y.; Song, W.; Yisimayi, A.; Du, S.; Zhang, Z.; Wang, Q.; et al. Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain. Emerg. Microbes Infect. 2024, 13, 2412990. [Google Scholar] [CrossRef]
  57. Walker, M.R.; Underwood, A.; Björnsson, K.H.; Raghavan, S.S.R.; Bassi, M.R.; Binderup, A.; Pham, L.V.; Ramirez, S.; Pinholt, M.; Dagil, R.; et al. Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages. Commun. Biol. 2024, 7, 1239. [Google Scholar] [CrossRef] [PubMed]
  58. Rubio, A.A.; Baharani, V.A.; Dadonaite, B.; Parada, M.; Abernathy, M.E.; Wang, Z.; Lee, Y.E.; Eso, M.R.; Phung, J.; Ramos, I.; et al. Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern. Sci. Transl. Med. 2025, 17, eadq5720. [Google Scholar] [CrossRef]
  59. Hong, Q.; Han, W.; Li, J.; Xu, S.; Wang, Y.; Xu, C.; Li, Z.; Wang, Y.; Zhang, C.; Huang, Z.; et al. Molecular basis of receptor binding and antibody neutralization of Omicron. Nature 2022, 604, 546–552. [Google Scholar] [CrossRef]
  60. Xu, S.; Wang, Y.; Wang, Y.; Zhang, C.; Hong, Q.; Gu, C.; Xu, R.; Wang, T.; Yang, Y.; Zang, J.; et al. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein. Emerg. Microbes Infect. 2022, 11, 351–367. [Google Scholar] [CrossRef] [PubMed]
  61. Jian, F.; Feng, L.; Yang, S.; Yu, Y.; Wang, L.; Song, W.; Yisimayi, A.; Chen, X.; Xu, Y.; Wang, P.; et al. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding. PLoS Pathog. 2023, 19, e1011868. [Google Scholar] [CrossRef]
  62. Liu, Y.; Zhao, X.; Shi, J.; Wang, Y.; Liu, H.; Hu, Y.F.; Hu, B.; Shuai, H.; Yuen, T.T.; Chai, Y.; et al. Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3. Nat. Commun. 2024, 15, 8728. [Google Scholar] [CrossRef]
  63. Yang, S.; Yu, Y.; Jian, F.; Song, W.; Yisimayi, A.; Chen, X.; Xu, Y.; Wang, P.; Wang, J.; Yu, L.; et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect. Dis. 2023, 23, e457–e459. [Google Scholar] [CrossRef]
  64. Zhou, D.; Supasa, P.; Liu, C.; Dijokaite-Guraliuc, A.; Duyvesteyn, H.M.E.; Selvaraj, M.; Mentzer, A.J.; Das, R.; Dejnirattisai, W.; Temperton, N.; et al. The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86. Nat. Commun. 2024, 15, 2734. [Google Scholar] [CrossRef]
  65. Seow, J.; Khan, H.; Rosa, A.; Calvaresi, V.; Graham, C.; Pickering, S.; Pye, V.E.; Cronin, N.B.; Huettner, I.; Malim, M.H.; et al. A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination. Cell Rep. 2022, 40, 111276. [Google Scholar] [CrossRef]
  66. Bianchini, F.; Crivelli, V.; Abernathy, M.E.; Guerra, C.; Palus, M.; Muri, J.; Marcotte, H.; Piralla, A.; Pedotti, M.; De Gasparo, R.; et al. Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. Sci. Immunol. 2023, 8, eade0958. [Google Scholar] [CrossRef]
  67. Guenthoer, J.; Lilly, M.; Starr, T.N.; Dadonaite, B.; Lovendahl, K.N.; Croft, J.T.; Stoddard, C.I.; Chohan, V.; Ding, S.; Ruiz, F.; et al. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection. Proc. Natl. Acad. Sci. USA 2023, 120, e2220948120. [Google Scholar] [CrossRef] [PubMed]
  68. Ishimaru, H.; Nishimura, M.; Shigematsu, H.; Marini, M.I.; Hasegawa, N.; Takamiya, R.; Iwata, S.; Mori, Y. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein. J. Virol. 2024, 98, e0041624. [Google Scholar] [CrossRef] [PubMed]
  69. Guo, L.; Lin, S.; Chen, Z.; Cao, Y.; He, B.; Lu, G. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. Signal Transduct. Target. Ther. 2023, 8, 197. [Google Scholar] [CrossRef] [PubMed]
  70. Sun, X.; Yi, C.; Zhu, Y.; Ding, L.; Xia, S.; Chen, X.; Liu, M.; Gu, C.; Lu, X.; Fu, Y.; et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nat. Microbiol. 2022, 7, 1063–1074. [Google Scholar] [CrossRef]
  71. Guenthoer, J.; Garrett, M.E.; Lilly, M.; Depierreux, D.M.; Ruiz, F.; Chi, M.; Stoddard, C.I.; Chohan, V.; Yaffe, Z.A.; Sung, K.; et al. The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2. PLoS Pathog. 2024, 20, e1012383. [Google Scholar] [CrossRef]
  72. Dacon, C.; Tucker, C.; Peng, L.; Lee, C.D.; Lin, T.H.; Yuan, M.; Cong, Y.; Wang, L.; Purser, L.; Williams, J.K.; et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science 2022, 377, 728–735. [Google Scholar] [CrossRef]
  73. Low, J.S.; Jerak, J.; Tortorici, M.A.; McCallum, M.; Pinto, D.; Cassotta, A.; Foglierini, M.; Mele, F.; Abdelnabi, R.; Weynand, B.; et al. ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science 2022, 377, 735–742. [Google Scholar] [CrossRef]
  74. Pinto, D.; Sauer, M.M.; Czudnochowski, N.; Low, J.S.; Tortorici, M.A.; Housley, M.P.; Noack, J.; Walls, A.C.; Bowen, J.E.; Guarino, B.; et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 2021, 373, 1109–1116. [Google Scholar] [CrossRef]
  75. Hurlburt, N.K.; Homad, L.J.; Sinha, I.; Jennewein, M.F.; MacCamy, A.J.; Wan, Y.H.; Boonyaratanakornkit, J.; Sholukh, A.M.; Jackson, A.M.; Zhou, P.; et al. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. Commun. Biol. 2022, 5, 342. [Google Scholar] [CrossRef] [PubMed]
  76. Jennewein, M.F.; MacCamy, A.J.; Akins, N.R.; Feng, J.; Homad, L.J.; Hurlburt, N.K.; Seydoux, E.; Wan, Y.H.; Stuart, A.B.; Edara, V.V.; et al. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep. 2021, 36, 109353. [Google Scholar] [CrossRef] [PubMed]
  77. Li, W.; Chen, Y.; Prévost, J.; Ullah, I.; Lu, M.; Gong, S.Y.; Tauzin, A.; Gasser, R.; Vézina, D.; Anand, S.P.; et al. Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell Rep. 2022, 38, 110210. [Google Scholar] [CrossRef]
  78. Song, G.; He, W.-T.; Callaghan, S.; Anzanello, F.; Huang, D.; Ricketts, J.; Torres, J.L.; Beutler, N.; Peng, L.; Vargas, S.; et al. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat. Commun. 2021, 12, 2938. [Google Scholar] [CrossRef]
  79. Zhou, P.; Yuan, M.; Song, G.; Beutler, N.; Shaabani, N.; Huang, D.; He, W.-T.; Zhu, X.; Callaghan, S.; Yong, P.; et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci. Transl. Med. 2022, 14, eabi9215. [Google Scholar] [CrossRef]
  80. Li, C.J.; Chao, T.L.; Chang, T.Y.; Hsiao, C.C.; Lu, D.C.; Chiang, Y.W.; Lai, G.C.; Tsai, Y.M.; Fang, J.T.; Ieong, S.; et al. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion. Microbiol. Spectr. 2022, 10, e0181421. [Google Scholar] [CrossRef]
  81. Shi, W.; Wang, L.; Zhou, T.; Sastry, M.; Yang, E.S.; Zhang, Y.; Chen, M.; Chen, X.; Choe, M.; Creanga, A.; et al. Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. Structure 2022, 30, 1233–1244.e1237. [Google Scholar] [CrossRef]
  82. Tan, S.S.E.; Tam, E.H.; Lai, K.M.; Wu, Y.; Xiao, T.; Tan, Y.J. Characterization of the Binding and Inhibition Mechanisms of a Novel Neutralizing Monoclonal Antibody Targeting the Stem Helix Region in the S2 Subunit of the Spike Protein of SARS-CoV-2. Vaccines 2025, 13, 688. [Google Scholar] [CrossRef] [PubMed]
  83. Piepenbrink, M.S.; Park, J.G.; Deshpande, A.; Loos, A.; Ye, C.; Basu, M.; Sarkar, S.; Khalil, A.M.; Chauvin, D.; Woo, J.; et al. Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody. PLoS Pathog. 2022, 18, e1010691. [Google Scholar] [CrossRef]
  84. Deshpande, A.; Schormann, N.; Piepenbrink, M.S.; Martinez Sobrido, L.; Kobie, J.J.; Walter, M.R. Structure and epitope of a neutralizing monoclonal antibody that targets the stem helix of β coronaviruses. FEBS J. 2023, 290, 3422–3435. [Google Scholar] [CrossRef]
  85. Zhou, P.; Song, G.; Liu, H.; Yuan, M.; He, W.T.; Beutler, N.; Zhu, X.; Tse, L.V.; Martinez, D.R.; Schäfer, A.; et al. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity 2023, 56, 669–686.e667. [Google Scholar] [CrossRef]
  86. Dacon, C.; Peng, L.; Lin, T.H.; Tucker, C.; Lee, C.D.; Cong, Y.; Wang, L.; Purser, L.; Cooper, A.J.R.; Williams, J.K.; et al. Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. Cell Host Microbe 2023, 31, 97–111.e112. [Google Scholar] [CrossRef]
  87. Wang, C.; van Haperen, R.; Gutiérrez-Álvarez, J.; Li, W.; Okba, N.M.A.; Albulescu, I.; Widjaja, I.; van Dieren, B.; Fernandez-Delgado, R.; Sola, I.; et al. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat. Commun. 2021, 12, 1715. [Google Scholar] [CrossRef]
  88. Sauer, M.M.; Tortorici, M.A.; Park, Y.-J.; Walls, A.C.; Homad, L.; Acton, O.J.; Bowen, J.E.; Wang, C.; Xiong, X.; de van der Schueren, W.; et al. Structural basis for broad coronavirus neutralization. Nat. Struct. Mol. Biol. 2021, 28, 478–486. [Google Scholar] [CrossRef]
  89. Hsieh, C.-L.; Werner, A.P.; Leist, S.R.; Stevens, L.J.; Falconer, E.; Goldsmith, J.A.; Chou, C.-W.; Abiona, O.M.; West, A.; Westendorf, K.; et al. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Rep. 2021, 37, 109929. [Google Scholar] [CrossRef]
  90. Yan, L.; Wang, F.; Hill, M.; Brun, J.; Liang, Z.; Shi, X.; Zhang, L.; He, X.; Li, Y.; Huang, Q.; et al. A broadly neutralizing antibody recognizes a unique epitope with a signature motif common across coronaviruses. Nat. Commun. 2025, 16, 7580. [Google Scholar] [CrossRef] [PubMed]
  91. Silva, R.P.; Huang, Y.; Nguyen, A.W.; Hsieh, C.-L.; Olaluwoye, O.S.; Kaoud, T.S.; Wilen, R.E.; Qerqez, A.N.; Park, J.-G.; Khalil, A.M.; et al. Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses. eLife 2023, 12, e83710. [Google Scholar] [CrossRef] [PubMed]
  92. Wu, W.L.; Chiang, C.Y.; Lai, S.C.; Yu, C.Y.; Huang, Y.L.; Liao, H.C.; Liao, C.L.; Chen, H.W.; Liu, S.J. Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants. JCI Insight 2022, 7, e157597. [Google Scholar] [CrossRef]
  93. Muyldermans, S. Nanobodies: Natural single-domain antibodies. Annu. Rev. Biochem. 2013, 82, 775–797. [Google Scholar] [CrossRef] [PubMed]
  94. Steeland, S.; Vandenbroucke, R.E.; Libert, C. Nanobodies as therapeutics: Big opportunities for small antibodies. Drug Discov. Today 2016, 21, 1076–1113. [Google Scholar] [CrossRef]
  95. Ye, G.; Bu, F.; Saxena, D.; Turner-Hubbard, H.; Herbst, M.; Spiller, B.; Wadzinski, B.E.; Du, L.; Liu, B.; Zheng, J.; et al. Discovery of Nanosota-9 as anti-Omicron nanobody therapeutic candidate. PLoS Pathog. 2024, 20, e1012726. [Google Scholar] [CrossRef]
  96. Aksu, M.; Kumar, P.; Güttler, T.; Taxer, W.; Gregor, K.; Mußil, B.; Rymarenko, O.; Stegmann, K.M.; Dickmanns, A.; Gerber, S.; et al. Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters. Antivir. Res. 2024, 221, 105778. [Google Scholar] [CrossRef]
  97. Shcheblyakov, D.V.; Favorskaya, I.A.; Dolzhikova, I.V.; Korobkova, A.I.; Alekseeva, I.A.; Esmagambetov, I.B.; Voronina, O.L.; Tukhvatulin, A.I.; Zubkova, O.V.; Derkaev, A.A.; et al. Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar activity. Int. J. Biol. Macromol. 2025, 319, 145386. [Google Scholar] [CrossRef]
  98. Dong, H.; Zhou, R.; Chen, J.; Wei, J.; Wei, Z.; Yang, Z.; Zhu, K.; Yang, Y.; Yang, Q.; Liu, N.; et al. Super broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1. PLoS Pathog. 2024, 20, e1012625. [Google Scholar] [CrossRef]
  99. He, L.; Wu, Q.; Zhang, Z.; Chen, L.; Yu, K.; Li, L.; Jia, Q.; Wang, Y.; Ni, J.; Wang, C.; et al. Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants. Mol. Pharm. 2024, 21, 3866–3879. [Google Scholar] [CrossRef]
  100. Modhiran, N.; Lauer, S.M.; Amarilla, A.A.; Hewins, P.; Lopes van den Broek, S.I.; Low, Y.S.; Thakur, N.; Liang, B.; Nieto, G.V.; Jung, J.; et al. A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants. iScience 2023, 26, 107085. [Google Scholar] [CrossRef]
  101. Yao, H.; Wang, H.; Zhang, Z.; Lu, Y.; Zhang, Z.; Zhang, Y.; Xiong, X.; Wang, Y.; Wang, Z.; Yang, H.; et al. A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains. MedComm 2023, 4, e397. [Google Scholar] [CrossRef] [PubMed]
  102. Li, M.; Ren, Y.; Aw, Z.Q.; Chen, B.; Yang, Z.; Lei, Y.; Cheng, L.; Liang, Q.; Hong, J.; Yang, Y.; et al. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. Nat. Commun. 2022, 13, 7957. [Google Scholar] [CrossRef] [PubMed]
  103. Zhao, D.; Liu, L.; Liu, X.; Zhang, J.; Yin, Y.; Luan, L.; Jiang, D.; Yang, X.; Li, L.; Xiong, H.; et al. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode. J. Nanobiotechnol. 2022, 20, 411. [Google Scholar] [CrossRef] [PubMed]
  104. Yang, Y.; Zhang, J.; Zhang, S.; Zhang, C.; Shen, C.; Song, S.; Wang, Y.; Peng, Y.; Gong, X.; Dai, J.; et al. A novel nanobody broadly neutralizes SARS-CoV-2 via induction of spike trimer dimers conformation. Exploration 2024, 4, 20230086. [Google Scholar] [CrossRef]
  105. Liu, B.; Liu, H.; Han, P.; Wang, X.; Wang, C.; Yan, X.; Lei, W.; Xu, K.; Zhou, J.; Qi, J.; et al. Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain. Signal Transduct. Target. Ther. 2024, 9, 131. [Google Scholar] [CrossRef]
  106. Guo, L.; Chen, Z.; Lin, S.; Yang, F.; Yang, J.; Wang, L.; Zhang, X.; Yuan, X.; He, B.; Cao, Y.; et al. Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants. PLoS Pathog. 2025, 21, e1013034. [Google Scholar] [CrossRef]
  107. De Cae, S.; Van Molle, I.; van Schie, L.; Shoemaker, S.R.; Deckers, J.; Debeuf, N.; Lameire, S.; Nerinckx, W.; Roose, K.; Fijalkowska, D.; et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base. Nat. Commun. 2025, 16, 5040. [Google Scholar] [CrossRef] [PubMed]
  108. Feng, B.; Li, C.; Zhang, Z.; Huang, Y.; Liu, B.; Zhang, Z.; Luo, J.; Wang, Q.; Yin, L.; Chen, S.; et al. A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses. J. Nanobiotechnol. 2025, 23, 110. [Google Scholar] [CrossRef]
  109. Buffington, J.; Duan, Z.; Kwon, H.J.; Hong, J.; Li, D.; Feng, M.; Xie, H.; Ho, M. Identification of nurse shark V(NAR) single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2. FASEB J. 2023, 37, e22973. [Google Scholar] [CrossRef]
  110. Korobkova, A.I.; Favorskaya, I.A.; Shuliakova, I.V.; Iliukhina, A.A.; Grousova, D.M.; Alekseeva, I.A.; Ryabova, E.I.; Derkaev, A.A.; Azizyan, V.V.; Zorkov, I.D.; et al. Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variants. Front. Immunol. 2026, 17, 1799333. [Google Scholar] [CrossRef]
  111. Clarke, J.; Jones, L.; Buckle, I.; Sharma, P.; Park, E.; Kipar, A.; Kirby, A.; Mega, D.; Ramadurai, S.; Karmakar, A.; et al. Nanobodies against the S2 region of the spike protein potently neutralize SARS-CoV-2 viruses and show resistance to virus escape. bioRxiv 2026, 2026.2001.2008.698330. [Google Scholar] [CrossRef]
  112. Moutinho, I.; Marimon, R.; Silva, R.D.M.; Fernandes, C.; Gano, L.; Correia, J.D.G.; Gonçalves, J.; Tavares, L.; Aires-da-Silva, F. A rabbit-derived single-domain antibody fused to the Streptococcus zooepidemicus Zag protein engineered for SARS-CoV-2 neutralization and extended half-life. Biologics 2026, 6, 10. [Google Scholar] [CrossRef]
  113. Iacobucci, G. COVID-19: FDA removes US authorisation for antibody drug Evusheld. BMJ 2023, 380, 264. [Google Scholar] [CrossRef] [PubMed]
  114. Nikitin, P.A.; DiMuzio, J.M.; Dowling, J.P.; Patel, N.B.; Bingaman-Steele, J.L.; Heimbach, B.C.; Henriquez, N.; Nicolescu, C.; Polley, A.; Sikorski, E.L.; et al. IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2. Sci. Immunol. 2022, 7, eabl9943. [Google Scholar] [CrossRef]
  115. Jiang, W.; Jiang, Y.; Sun, H.; Deng, T.; Yu, K.; Fang, Q.; Ge, H.; Lan, M.; Lin, Y.; Fang, Z.; et al. Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harbouring both NTD and RBD potent antibodies. Emerg. Microbes Infect. 2024, 13, 2406300. [Google Scholar] [CrossRef] [PubMed]
  116. ClinicalTrials. IMM-BCP-01 in Mild to Moderate COVID-19. Available online: https://clinicaltrials.gov/study/NCT05429021?intr=IMM-BCP-01&viewType=Card&rank=1 (accessed on 28 May 2026).
  117. Sun, Y.; Wang, L.; Feng, R.; Wang, N.; Wang, Y.; Zhu, D.; Xing, X.; Yang, P.; Zhang, Y.; Li, W.; et al. Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms. Cell Res. 2021, 31, 597–600. [Google Scholar] [CrossRef]
  118. Baum, A.; Fulton, B.O.; Wloga, E.; Copin, R.; Pascal, K.E.; Russo, V.; Giordano, S.; Lanza, K.; Negron, N.; Ni, M.; et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 2020, 369, 1014–1018. [Google Scholar] [CrossRef]
  119. Cao, Y.; Jian, F.; Zhang, Z.; Yisimayi, A.; Hao, X.; Bao, L.; Yuan, F.; Yu, Y.; Du, S.; Wang, J.; et al. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep. 2022, 41, 111845. [Google Scholar] [CrossRef]
  120. Ma, H.; Zong, H.F.; Liu, J.J.; Yue, Y.L.; Ke, Y.; Liao, Y.J.; Tang, H.N.; Wang, L.; Wang, S.S.; Yuan, Y.S.; et al. Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails. Acta Pharmacol. Sin. 2023, 44, 1455–1463. [Google Scholar] [CrossRef] [PubMed]
  121. U.S. Food and Drug Administration. FDA Authorizes REGEN-COV Monoclonal Antibody Therapy for Post-Exposure Prophylaxis (Prevention) for COVID-19. Available online: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19 (accessed on 28 May 2026).
  122. ClinicalTrials. SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients. Available online: https://clinicaltrials.gov/study/NCT06042764?intr=SA55&viewType=Card&rank=1 (accessed on 28 May 2026).
  123. Ullah, I.; Prévost, J.; Ladinsky, M.S.; Stone, H.; Lu, M.; Anand, S.P.; Beaudoin-Bussières, G.; Symmes, K.; Benlarbi, M.; Ding, S.; et al. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity 2021, 54, 2143–2158.e2115. [Google Scholar] [CrossRef]
  124. Dussupt, V.; Sankhala, R.S.; Mendez-Rivera, L.; Townsley, S.M.; Schmidt, F.; Wieczorek, L.; Lal, K.G.; Donofrio, G.C.; Tran, U.; Jackson, N.D.; et al. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nat. Immunol. 2021, 22, 1503–1514. [Google Scholar] [CrossRef]
  125. Beaudoin-Bussières, G.; Chen, Y.; Ullah, I.; Prévost, J.; Tolbert, W.D.; Symmes, K.; Ding, S.; Benlarbi, M.; Gong, S.Y.; Tauzin, A.; et al. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Cell Rep. 2022, 38, 110368. [Google Scholar] [CrossRef] [PubMed]
  126. Roodink, I.; van Erp, M.; Li, A.; Potter, S.; van Duijnhoven, S.M.J.; Smits, M.; Kuipers, A.J.; Kazemier, B.; Berkeveld, B.; van Geffen, E.; et al. Broad Epitope Coverage of Therapeutic Multi-Antibody Combinations Targeting SARS-CoV-2 Boosts In Vivo Protection and Neutralization Potency to Corner an Immune-Evading Virus. Biomedicines 2024, 12, 642. [Google Scholar] [CrossRef]
  127. Wang, Y.; Liu, M.; Shen, Y.; Ma, Y.; Li, X.; Zhang, Y.; Liu, M.; Yang, X.L.; Chen, J.; Yan, R.; et al. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses. Cell Discov. 2022, 8, 36. [Google Scholar] [CrossRef]
  128. Inoue, T.; Yamamoto, Y.; Sato, K.; Okemoto-Nakamura, Y.; Shimizu, Y.; Ogawa, M.; Onodera, T.; Takahashi, Y.; Wakita, T.; Kaneko, M.K.; et al. Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies. iScience 2024, 27, 109363. [Google Scholar] [CrossRef]
  129. De Gasparo, R.; Pedotti, M.; Simonelli, L.; Nickl, P.; Muecksch, F.; Cassaniti, I.; Percivalle, E.; Lorenzi, J.C.C.; Mazzola, F.; Magrì, D.; et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature 2021, 593, 424–428. [Google Scholar] [CrossRef]
  130. Guerra, D.; Radić, L.; Brinkkemper, M.; Poniman, M.; van der Maas, L.; Torres, J.L.; Ward, A.B.; Sliepen, K.; Schinkel, J.; Sanders, R.W.; et al. Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain. Hum. Vaccines Immunother. 2024, 20, 2388344. [Google Scholar] [CrossRef]
  131. Chang, F.; Wu, Q.; Hu, Y.; Pan, Z.; Liu, Y.C.; Li, Y.Z.; Bostina, M.; Liu, W.; Zhao, P.; Qu, X.; et al. Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses. Med. Microbiol. Immunol. 2024, 213, 24. [Google Scholar] [CrossRef]
  132. Lim, S.A.; Gramespacher, J.A.; Pance, K.; Rettko, N.J.; Solomon, P.; Jin, J.; Lui, I.; Elledge, S.K.; Liu, J.; Bracken, C.J.; et al. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2. mAbs 2021, 13, 1893426. [Google Scholar] [CrossRef] [PubMed]
  133. Qiao, R.; Liu, Y.; Mao, Q.; Li, J.; Lu, Y.; Shi, J.; Li, C.; Yu, J.; Gong, J.; Wang, X.; et al. Novel Trispecific Neutralizing Antibodies with Enhanced Potency and Breadth Against Pan-Sarbecoviruses. MedComm 2025, 6, e70191. [Google Scholar] [CrossRef] [PubMed]
  134. Li, C.; Zhan, W.; Yang, Z.; Tu, C.; Hu, G.; Zhang, X.; Song, W.; Du, S.; Zhu, Y.; Huang, K.; et al. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell 2022, 185, 1389–1401.e1318. [Google Scholar] [CrossRef] [PubMed]
  135. Hollingsworth, S.A.; Noland, C.L.; Vroom, K.; Saha, A.; Sam, M.; Gao, Q.; Zhou, H.; Grandy, D.U.; Singh, S.; Wen, Z.; et al. Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants. Sci. Rep. 2023, 13, 13668. [Google Scholar] [CrossRef]
  136. Yuan, M.; Zhu, Y.; Liu, G.; Wang, Y.; Wang, G.; Zhang, G.; Ye, L.; Qian, Z.; Liu, P. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant. One Health Adv. 2023, 1, 12. [Google Scholar] [CrossRef]
  137. Sun, H.; Xia, L.; Li, J.; Zhang, Y.; Zhang, G.; Huang, P.; Wang, X.; Cui, Y.; Fang, T.; Fan, P.; et al. A novel bispecific antibody targeting two overlapping epitopes in RBD improves neutralizing potency and breadth against SARS-CoV-2. Emerg. Microbes Infect. 2024, 13, 2373307. [Google Scholar] [CrossRef]
  138. Chi, X.; Zhang, X.; Pan, S.; Yu, Y.; Shi, Y.; Lin, T.; Duan, H.; Liu, X.; Chen, W.; Yang, X.; et al. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. Signal Transduct. Target. Ther. 2022, 7, 44. [Google Scholar] [CrossRef]
  139. Dong, J.; Huang, B.; Wang, B.; Titong, A.; Gallolu Kankanamalage, S.; Jia, Z.; Wright, M.; Parthasarathy, P.; Liu, Y. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2. Sci. Rep. 2020, 10, 17806. [Google Scholar] [CrossRef]
  140. Li, Z.; Li, S.; Zhang, G.; Peng, W.; Chang, Z.; Zhang, X.; Fan, Z.; Chai, Y.; Wang, F.; Zhao, X.; et al. An engineered bispecific human monoclonal antibody against SARS-CoV-2. Nat. Immunol. 2022, 23, 423–430. [Google Scholar] [CrossRef]
  141. Li, M.; Zhao, C.; Shi, J.; Wang, X.; Liu, Y.; Zhao, X.; Cai, G.; Chu, H.; Wang, P. Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes. Emerg. Microbes Infect. 2024, 13, 2404166. [Google Scholar] [CrossRef]
  142. ClinicalTrials. A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, PK and Immunogenicity of YBSW015 in Healthy Subjects. Available online: https://clinicaltrials.gov/study/NCT05369754?intr=YBSW015&viewType=Card&rank=1 (accessed on 28 May 2026).
  143. Chen, W.H.; Hajduczki, A.; Martinez, E.J.; Bai, H.; Matz, H.; Hill, T.M.; Lewitus, E.; Chang, W.C.; Dawit, L.; Peterson, C.E.; et al. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity. Nat. Commun. 2023, 14, 580. [Google Scholar] [CrossRef] [PubMed]
  144. Shi, Z.; Li, X.; Wang, L.; Sun, Z.; Zhang, H.; Chen, X.; Cui, Q.; Qiao, H.; Lan, Z.; Zhang, X.; et al. Structural basis of nanobodies neutralizing SARS-CoV-2 variants. Structure 2022, 30, 707–720.e705. [Google Scholar] [CrossRef] [PubMed]
  145. Wang, Y.; Hao, A.; Ji, P.; Ma, Y.; Zhang, Z.; Chen, J.; Mao, Q.; Xiong, X.; Rehati, P.; Wang, Y.; et al. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses. Nat. Commun. 2024, 15, 5127. [Google Scholar] [CrossRef] [PubMed]
  146. Yuan, M.; Chen, X.; Zhu, Y.; Dong, X.; Liu, Y.; Qian, Z.; Ye, L.; Liu, P. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. J. Virol. 2022, 96, e0077522. [Google Scholar] [CrossRef]
  147. Feng, H.; Wang, Z.; Li, L.; Li, Y.; Lu, M.; Chen, X.; Hu, L.; Sun, Y.; Du, R.; Qin, R.; et al. Discovery of Synergistic Broadly Neutralizing Antibodies Targeting Non-Dominant Epitopes on SARS-CoV-2 RBD and NTD. Vaccines 2025, 13, 592. [Google Scholar] [CrossRef]
  148. Misasi, J.; Wei, R.R.; Wang, L.; Pegu, A.; Wei, C.J.; Oloniniyi, O.K.; Zhou, T.; Moliva, J.I.; Zhao, B.; Choe, M.; et al. A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo. Sci. Transl. Med. 2024, 16, eado9026. [Google Scholar] [CrossRef]
  149. Cho, H.; Gonzales-Wartz, K.K.; Huang, D.; Yuan, M.; Peterson, M.; Liang, J.; Beutler, N.; Torres, J.L.; Cong, Y.; Postnikova, E.; et al. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Sci. Transl. Med. 2021, 13, eabj5413. [Google Scholar] [CrossRef] [PubMed]
  150. Wang, Y.; Zhang, X.; Ma, Y.; Wang, Y.; Zhan, W.; Zheng, Q.; Zhang, M.; Ji, P.; Liu, M.; Liu, Q.; et al. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. Cell Discov. 2022, 8, 104. [Google Scholar] [CrossRef]
  151. Ku, Z.; Xie, X.; Lin, J.; Gao, P.; Wu, B.; El Sahili, A.; Su, H.; Liu, Y.; Ye, X.; Tan, E.Y.; et al. Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth. Nat. Commun. 2022, 13, 5552. [Google Scholar] [CrossRef]
  152. Walter, J.D.; Scherer, M.; Hutter, C.A.J.; Garaeva, A.A.; Zimmermann, I.; Wyss, M.; Rheinberger, J.; Ruedin, Y.; Earp, J.C.; Egloff, P.; et al. Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. EMBO Rep. 2022, 23, e54199. [Google Scholar] [CrossRef]
  153. Lázaro-Gorines, R.; Pérez, P.; Heras-Murillo, I.; Adán-Barrientos, I.; Albericio, G.; Astorgano, D.; Flores, S.; Luczkowiak, J.; Labiod, N.; Harwood, S.L.; et al. Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2. Adv. Sci. 2023, 10, e2304818. [Google Scholar] [CrossRef]
  154. Ma, Y.; Liu, Q.; Rehati, P.; Zhang, Z.; Wang, Y.; Liu, Z.; Chen, J.; Bai, X.; Hao, A.; Wang, Y.; et al. Structure-guided bispecific antibody engineering confers broad protection against KP.3.1.1 and sarbecoviruses. iScience 2025, 28, 113175. [Google Scholar] [CrossRef]
  155. Huang, Y.; Lin, Z.; Guo, X.; Zhang, F.; Wang, Y.; Zhang, Z.; Chen, J.; Liu, L.; Zhu, M.; Li, Y.; et al. Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials. Virol. J. 2025, 22, 358. [Google Scholar] [CrossRef] [PubMed]
  156. Wang, Z.; Lorenzi, J.C.C.; Muecksch, F.; Finkin, S.; Viant, C.; Gaebler, C.; Cipolla, M.; Hoffmann, H.H.; Oliveira, T.Y.; Oren, D.A.; et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 2021, 13, eabf1555. [Google Scholar] [CrossRef]
  157. Marcotte, H.; Cao, Y.; Zuo, F.; Simonelli, L.; Sammartino, J.C.; Pedotti, M.; Sun, R.; Cassaniti, I.; Hagbom, M.; Piralla, A.; et al. Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages. Proc. Natl. Acad. Sci. USA 2024, 121, e2315354120. [Google Scholar] [CrossRef]
  158. Planchais, C.; Fernández, I.; Bruel, T.; de Melo, G.D.; Prot, M.; Beretta, M.; Guardado-Calvo, P.; Dufloo, J.; Molinos-Albert, L.M.; Backovic, M.; et al. Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. J. Exp. Med. 2022, 219, e20220638. [Google Scholar] [CrossRef] [PubMed]
  159. Ejemel, M.; Li, Q.; Hou, S.; Schiller, Z.A.; Tree, J.A.; Wallace, A.; Amcheslavsky, A.; Kurt Yilmaz, N.; Buttigieg, K.R.; Elmore, M.J.; et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat. Commun. 2020, 11, 4198. [Google Scholar] [CrossRef]
  160. Zhang, G.; Huang, P.; Yuan, H.; Li, E.; Chi, X.; Sun, H.; Han, J.; Fang, T.; Dong, Y.; Li, J.; et al. Nasal delivery of secretory IgA confers enhanced neutralizing activity against Omicron variants compared to its IgG counterpart. Mol. Ther. 2025, 33, 1687–1700. [Google Scholar] [CrossRef]
  161. Sun, L.; Kallolimath, S.; Palt, R.; Stiasny, K.; Mayrhofer, P.; Maresch, D.; Eidenberger, L.; Steinkellner, H. Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG. Proc. Natl. Acad. Sci. USA 2021, 118, e2107148118. [Google Scholar] [CrossRef]
  162. Zuo, F.; Cao, Y.; Sun, R.; Wang, Q.; Simonelli, L.; Du, L.; Bertoglio, F.; Schubert, M.; Guerra, C.; Cavalli, A.; et al. Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants. J. Virol. 2025, 99, e01740-24. [Google Scholar] [CrossRef] [PubMed]
  163. Zeng, W.; Jia, X.; Chi, X.; Zhang, X.; Li, E.; Wu, Y.; Liu, Y.; Han, J.; Ni, K.; Ye, X.; et al. An engineered bispecific nanobody in tetrameric secretory IgA format confers broad neutralization against SARS-CoV-1&2 and most variants. Int. J. Biol. Macromol. 2023, 253, 126817. [Google Scholar] [CrossRef] [PubMed]
  164. Bolton, M.J.; Santos, J.J.S.; Arevalo, C.P.; Griesman, T.; Watson, M.; Li, S.H.; Bates, P.; Ramage, H.; Wilson, P.C.; Hensley, S.E. IgG3 subclass antibodies recognize antigenically drifted influenza viruses and SARS-CoV-2 variants through efficient bivalent binding. Proc. Natl. Acad. Sci. USA 2023, 120, e2216521120. [Google Scholar] [CrossRef]
  165. Ku, Z.; Xie, X.; Hinton, P.R.; Liu, X.; Ye, X.; Muruato, A.E.; Ng, D.C.; Biswas, S.; Zou, J.; Liu, Y.; et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature 2021, 595, 718–723. [Google Scholar] [CrossRef] [PubMed]
  166. Liu, H.; Wu, L.; Liu, B.; Xu, K.; Lei, W.; Deng, J.; Rong, X.; Du, P.; Wang, L.; Wang, D.; et al. Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice. Cell Rep. Med. 2023, 4, 100918. [Google Scholar] [CrossRef]
  167. Jiang, X.; Qin, Q.; Zhu, H.; Qian, J.; Huang, Q. Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein. Int. J. Biol. Macromol. 2024, 256, 128191. [Google Scholar] [CrossRef]
  168. Weinstein, J.B.; Bates, T.A.; Leier, H.C.; McBride, S.K.; Barklis, E.; Tafesse, F.G. A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. iScience 2022, 25, 103960. [Google Scholar] [CrossRef]
  169. Swart, I.C.; Debski-Antoniak, O.J.; Zegar, A.; de Bouter, T.; Chatziandreou, M.; van den Berg, M.; Drulyte, I.; Pyrć, K.; de Haan, C.A.M.; Hurdiss, D.L.; et al. A bivalent spike-targeting nanobody with anti-sarbecovirus activity. J. Nanobiotechnol. 2025, 23, 196. [Google Scholar] [CrossRef]
  170. Xu, J.; Xu, K.; Jung, S.; Conte, A.; Lieberman, J.; Muecksch, F.; Lorenzi, J.C.C.; Park, S.; Schmidt, F.; Wang, Z.; et al. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature 2021, 595, 278–282. [Google Scholar] [CrossRef]
  171. Sun, H.; Jiang, Y.; Lan, M.; Zhou, M.; Yi, G.; Shen, J.; Deng, T.; Liu, L.; Huang, Y.; Li, Y.; et al. Engineering a multivalent antibody nanoparticle to overcome SARS-CoV-2 Omicron immune evasion. PLoS Pathog. 2025, 21, e1013744. [Google Scholar] [CrossRef]
  172. Wang, Y.; Song, F.; Wang, S.; Lan, M.; Li, T.; Guo, H.; Zhang, Y.; Ge, S.; Zheng, Z.; Xia, N. Nanoparticle-based multivalent human antibodies offer potent and broad neutralization against Omicron sublineages. Signal Transduct. Target. Ther. 2023, 8, 284. [Google Scholar] [CrossRef]
  173. Lu, Y.; Li, Q.; Fan, H.; Liao, C.; Zhang, J.; Hu, H.; Yi, H.; Peng, Y.; Lu, J.; Chen, Z. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529). Int. J. Nanomed. 2023, 18, 353–367. [Google Scholar] [CrossRef]
  174. Izadi, A.; Nordenfelt, P. Protective non-neutralizing SARS-CoV-2 monoclonal antibodies. Trends Immunol. 2024, 45, 609–624. [Google Scholar] [CrossRef]
  175. Bahnan, W.; Wrighton, S.; Sundwall, M.; Bläckberg, A.; Larsson, O.; Höglund, U.; Khakzad, H.; Godzwon, M.; Walle, M.; Elder, E.; et al. Spike-dependent opsonization indicates both dose-dependent inhibition of phagocytosis and that non-neutralizing antibodies can confer protection to SARS-CoV-2. Front. Immunol. 2021, 12, 808932. [Google Scholar] [CrossRef] [PubMed]
  176. Pierre, C.N.; Adams, L.E.; Higgins, J.S.; Anasti, K.; Goodman, D.; Mielke, D.; Stanfield-Oakley, S.; Powers, J.M.; Li, D.; Rountree, W.; et al. Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions. PLoS Pathog. 2024, 20, e1011569. [Google Scholar] [CrossRef] [PubMed]
  177. Tan, T.J.C.; Verma, A.K.; Odle, A.; Lei, R.; Meyerholz, D.K.; Matreyek, K.A.; Perlman, S.; Wong, L.R.; Wu, N.C. Evidence of antigenic drift in the fusion machinery core of SARS-CoV-2 spike. Proc. Natl. Acad. Sci. USA 2024, 121, e2317222121. [Google Scholar] [CrossRef]
  178. Yamin, R.; Jones, A.T.; Hoffmann, H.H.; Schäfer, A.; Kao, K.S.; Francis, R.L.; Sheahan, T.P.; Baric, R.S.; Rice, C.M.; Ravetch, J.V.; et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 2021, 599, 465–470. [Google Scholar] [CrossRef] [PubMed]
  179. Izadi, A.; Hailu, A.; Godzwon, M.; Wrighton, S.; Olofsson, B.; Schmidt, T.; Söderlund-Strand, A.; Elder, E.; Appelberg, S.; Valsjö, M.; et al. Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization. Proc. Natl. Acad. Sci. USA 2023, 120, e2217590120. [Google Scholar] [CrossRef]
  180. Johnson, N.V.; Wall, S.C.; Kramer, K.J.; Holt, C.M.; Periasamy, S.; Richardson, S.I.; Manamela, N.P.; Suryadevara, N.; Andreano, E.; Paciello, I.; et al. Discovery and characterization of a pan-betacoronavirus S2-binding antibody. Structure 2024, 32, 1893–1909.e1811. [Google Scholar] [CrossRef] [PubMed]
  181. Loo, Y.-M.; McTamney, P.M.; Arends, R.H.; Abram, M.E.; Aksyuk, A.A.; Diallo, S.; Flores, D.J.; Kelly, E.J.; Ren, K.; Roque, R.; et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci. Transl. Med. 2022, 14, eabl8124. [Google Scholar] [CrossRef] [PubMed]
  182. Wang, Y.; Hu, Y.; Ku, Z.; Yeung, J.; Zou, J.; Woodson, M.; Prokhorov, N.S.; Knyazhanskaya, E.S.; Zhao, H.; Sherman, M.B.; et al. Neutralization of SARS-CoV-2 by IgM-14 via engagement of two distinct spike epitopes. PLoS Pathog. 2026, 22, e1014071. [Google Scholar] [CrossRef] [PubMed]
  183. Golonka, R.M.; Intravaia, L.E.; Shaqra, A.M.; Li, Q.; Chen, Y.; Humphries, F.; Kurt-Yilmaz, N.; Fitzgerald, K.A.; Schiffer, C.A.; Wang, Y.; et al. Engineered IgA-Fc fusion protein with bioactive nanobody neutralizes SARS-CoV-2 variants with mucosal delivery potential. J. Biol. Chem. 2026, 302, 111210. [Google Scholar] [CrossRef]
  184. Cerdán, L.; Silva, K.; Rodríguez-Martín, D.; Pérez, P.; Noriega, M.A.; Esteban Martín, A.; Gutiérrez-Adán, A.; Margolles, Y.; Corbera, J.A.; Martín-Acebes, M.A.; et al. Integrating immune library probing with structure-based computational design to develop potent neutralizing nanobodies against emerging SARS-CoV-2 variants. mAbs 2025, 17, 2499595. [Google Scholar] [CrossRef]
  185. Wasdin, P.T.; Johnson, N.V.; Janke, A.K.; Held, S.; Marinov, T.M.; Jordaan, G.; Gillespie, R.A.; Vandenabeele, L.; Pantouli, F.; Powers, O.C.; et al. Generation of antigen-specific paired-chain antibodies using large language models. Cell 2025, 188, 7206–7221.e7216. [Google Scholar] [CrossRef]
  186. Desautels, T.A.; Arrildt, K.T.; Zemla, A.T.; Lau, E.Y.; Zhu, F.; Ricci, D.; Cronin, S.; Zost, S.J.; Binshtein, E.; Scheaffer, S.M.; et al. Computationally restoring the potency of a clinical antibody against Omicron. Nature 2024, 629, 878–885. [Google Scholar] [CrossRef]
  187. Swanson, K.; Wu, W.; Bulaong, N.L.; Pak, J.E.; Zou, J. The Virtual Lab of AI agents designs new SARS-CoV-2 nanobodies. Nature 2025, 646, 716–723. [Google Scholar] [CrossRef]
Viruses 18 00642 g001
Figure 1. Representative antibodies and nanobodies targeting the SARS-CoV-2 spike. Antibody/antigen complex structures are from the Protein Data Bank (PDB). The spike trimer (PDB: 7N1Q) is shown using a bimodal representation. Two of the protomers are displayed with their molecular surfaces in dark and grey, the third protomer is illustrated as a cartoon. Representative binding patterns of neutralizing antibodies targeting various epitopes on the S protein, RBD-ACE2 (6M0J), S2K146 (7TAT), D1F6 (8ZBY), S309 (7R6W), CR3022 (6W41), 4A8 (7C2L), C1717 (7UAR), K501SP6 (9FJK), C1595 (9BJ3), S3H3 (7WK8), sd1.040 (8D48), VN01H1 (7SKZ), 76E1 (7X9E), fp.006 (8D47), C77G12 (7U0A), COV44.79 (8DAO), COV44.62 (8D36), B6 (7M53), IgG22 (7S3N), CC40.8 (7SJS), WS6 (7TCQ), CC25.106 (8DGU), S2P6 (7RNJ), CV3-25 (7RAQ), 1p1B10 (9IQP), 3-2A2-4 (7X2L), N235 (8JVA), H145 (9LDS). RBD, receptor-binding domain. NTD, N-terminal domain. SD1, subdomain 1. FP, fusion peptide. SH, stem helix.
Figure 1. Representative antibodies and nanobodies targeting the SARS-CoV-2 spike. Antibody/antigen complex structures are from the Protein Data Bank (PDB). The spike trimer (PDB: 7N1Q) is shown using a bimodal representation. Two of the protomers are displayed with their molecular surfaces in dark and grey, the third protomer is illustrated as a cartoon. Representative binding patterns of neutralizing antibodies targeting various epitopes on the S protein, RBD-ACE2 (6M0J), S2K146 (7TAT), D1F6 (8ZBY), S309 (7R6W), CR3022 (6W41), 4A8 (7C2L), C1717 (7UAR), K501SP6 (9FJK), C1595 (9BJ3), S3H3 (7WK8), sd1.040 (8D48), VN01H1 (7SKZ), 76E1 (7X9E), fp.006 (8D47), C77G12 (7U0A), COV44.79 (8DAO), COV44.62 (8D36), B6 (7M53), IgG22 (7S3N), CC40.8 (7SJS), WS6 (7TCQ), CC25.106 (8DGU), S2P6 (7RNJ), CV3-25 (7RAQ), 1p1B10 (9IQP), 3-2A2-4 (7X2L), N235 (8JVA), H145 (9LDS). RBD, receptor-binding domain. NTD, N-terminal domain. SD1, subdomain 1. FP, fusion peptide. SH, stem helix.
Viruses 18 00642 g001
Viruses 18 00642 g002
Figure 2. Schematic of representative bi-/multi-specific antibody formats. CrossMab, crossed monoclonal antibody; KIH, Knob-In-Hole; (scFv)2-IgG, dual single-chain Fv fused IgG; IgG-scFv, IgG with C-terminal scFv fusion; DVD-Ig, dual variable domain immunoglobulin; CODV-Ig, cross-over dual variable domains immunoglobulin; (VHH)2-trimer, dual VHH trimeric antibody; (VHH)2-trimer-scFv, dual VHH trimer with scFv fusion; scFv, single-chain variable fragment; sdAb, single domain antibody; VHH, variable domain of heavy chain of heavy-chain antibody; VNAR, shark variable new antigen receptor.
Figure 2. Schematic of representative bi-/multi-specific antibody formats. CrossMab, crossed monoclonal antibody; KIH, Knob-In-Hole; (scFv)2-IgG, dual single-chain Fv fused IgG; IgG-scFv, IgG with C-terminal scFv fusion; DVD-Ig, dual variable domain immunoglobulin; CODV-Ig, cross-over dual variable domains immunoglobulin; (VHH)2-trimer, dual VHH trimeric antibody; (VHH)2-trimer-scFv, dual VHH trimer with scFv fusion; scFv, single-chain variable fragment; sdAb, single domain antibody; VHH, variable domain of heavy chain of heavy-chain antibody; VNAR, shark variable new antigen receptor.
Viruses 18 00642 g002
Table 1. Representative SARS-CoV-2-specific nanobodies.
Table 1. Representative SARS-CoV-2-specific nanobodies.
NameOriginTargetAffinityNeutralizing Activity Against Omicron Sublineages (IC50)Neutralization Mechanism
Tnb04-1 [98]Isolated from immunized alpacasRBD, no competition with ACE2WT RBD (KD 0.648 nM)BA.1, BA.2, BA.4/5, BA.5.2, BF.7, BQ.1, BQ.1.1, XBB, XBB.1, XBB.1.5, XBB.1.16, CH.1.1, EG.5, EG.5.1, BA.2.86, HK3, HV.1, JD.1.1, JN.1, KP.3, KP.3.1.1 (0.007–0.03 μg/mL)Bound a conserved hydrophobic pocket in the RBD, disrupting formation of the proteinase K-resistant core required for viral-cell fusion.
Nb1 and Nb2 [99]Phage library from immunized alpacasRBD Variants S1s (KD 178–503 pM)BA.1, BA.2, BA.3, BA.5, BA.2.75, BF.7, BQ.1, EG.5.1, XBB.1.5, JN.1 (2.82–799.3 ng/mL)Directly interfered with RBD-ACE2 interaction.
Ma16B06, etc. [96]Phage library from immunized alpacasRBDVariants RBDs (KD 10–250 pM)BA.1, BA.2.75, BA.5, BQ.1, BJ.1, XBB.1 (50–250 pM)Occupied all three spike RBDs in both the up and down states.
W25 [100]Isolated from immunized alpacasRBDVariants spikes (KD 0.001–11.4 nM)BA.1, BA.2 (1.45–2.07 nM)Triggered premature fusogenic conformational changes in spike, leading to viral inactivation before cellular engagement.
Nb4 [101]Synthetic nanobody phage libraryRBDBA.1 RBD (KD 7.4 nM)BA.1.1, BA.2 (1.5–20 μg/mL)Competed with ACE2.
C5G2 [103]Synthetic nanobody phage libraryRBDWT RBD (KD 1.62 nM)BA.1 (0.3 nM)Steric hindrance from the FR2 of C5G2 inhibited ACE2-RBD binding.
3-2A2-4 [102]Yeast library from immunized alpacasRBDNABA.1, BA.2, BA.2.12.1, BA.4/5 (0.032–0.17 μg/mL)Suppressed the RBD transition from the down to the up state, thereby inhibiting ACE2 binding and viral entry.
1p1B10 [97]Phage library from immunized Bactrian camelRBMXBB.1 RBD (KD 0.73 nM)BA.1, BA.2, BA.5, XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16, EG.5.1, JN.1, KS.1 (0.06–5.34 pM)Competed with ACE2.
Nanosota-9 [95]Phage library from immunized alpacasRBDBA.5, XBB.1.5, JN.1 spikes (KD 0.06–29.4 nM)BA.5, XBB.1.5, JN.1, BA.2.75, BQ.1, EG.5, KP.2 (1–15 ng/mL)Two Nanosota-9 molecules crosslinked two spike RBDs.
IBT-CoV144 [104]Isolated from immunized alpacasRBD class 4BA.2, BA.2.75, BA.4/5, BF.7, BQ.1.1 RBDs (22.3–52.9 nM)BA.1, BA.2, BA.2.75, BA.4/5, BF.7, BQ.1.1 (331.4–722 ng/mL)Crosslinked two spikes, inducing spike aggregation.
N235 [105]Phage library from immunized alpacasNTDVariants spikes (KD < 0.3 nM)BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.3.20, BA.2.75, BA.3, BA.4/5, BQ.1.1, BF.7, XBB, XBB.1.5, XBB.1.16, CH.1.1, EG.5, EG.5.1, BA.2.86, JN.1 (0.3–7.2 μg/mL)Interfered with neighboring RBDs and induced S1 shedding from the trimeric spike.
H17 and H145 [106]Phage library from immunized alpacasSH (1139–1152)WT spike (KD 11.3–17.9 nM)BA.1, BA.2, BA.4/5, BA.2.12.1, BF.7, BA.2.75, XBB.1.5, XBB.1.16, JN.1, KP.3 (0.18–1.82 μg/mL)Bound the unexposed inner face of SH, disrupting the S2 fusion machinery.
79C11 [108]Phage library from immunized sharksHR1 (916–935)Variants spikes (KD 20.3–35.0 nM)BA.1, BA.2, BA.4, BF.7, BQ.1.1, XBB.1, XBB.1.5, XBB.1.16.1, EG.5, BA.2.86, JN.1, KP.2 (0.341–0.794 μg/mL)Obstructed HR1-HR2 interaction and 6HB formation, thereby inhibiting virus–host membrane fusion.
S2A9 [109]Phage library from immunized sharksS2WT S2 (KD 590 nM)BA.1, BA.2, BA.4/5 (2143–3733 ng/mL)Interfered with S2-mediated viral-cell membrane fusion.
1p2B5 [110]Phage library from immunized camelNTDXBB.1 NTD (KD 0.44 nM)XBB.1.9.1, EG.5.1, XBB.1.16, JN.1, KS.1 (0.17–1.23 nM)Inhibited membrane fusion rather than blocking S-ACE2 binding.
R3DC23 [107]Phage library from immunized llamaHR2WT S-2P (KD 0.17 nM)BA.1, BA.2, BA.2.75, BA.5, BA.4.6, BQ.1.1, XBB, BA.2.86, EG.5.1, KP.3, KP.2.3, KP.1.1, LB.1, XEC (close to or below 1 ng/mL)Clamped the prefusion HR2 coiled-coil and blocked 6HB formation.
BA.1-C2 and BA.1-D3 [111]Phage library from immunized llamaHR2BA.1 S2 (0.176 nM)BA.1, EG.5.1, JN.1, XBB.1.5 (0.018–2.09 nM)Clamped the prefusion HR2 coiled-coil and blocked 6HB formation.
B3 [112]VL sdAb library from immunized rabbit RBD, competition with ACE2NABA.1 (5.3 μM)Competed with ACE2.
NA, not available.
Table 2. Representative of antibody cocktails against SARS-CoV-2.
Table 2. Representative of antibody cocktails against SARS-CoV-2.
NameTypeComponentsEpitopesNeutralizing Activity Against Omicron Sublineages (IC50)In Vitro Synergistic Effects (Binding, Neutralization, ADCC)In Vivo Synergistic Effects (Animal Models)
9E12+10D4+2G1 [120]3-antibodies cocktail9E12RBD group 1BA.1 (4258 ng/mL)The cocktail remained resistant to viral escape after 30 passages and exhibited mutation tolerance far greater than either antibody alone.NA
10D4RBD group 2
2G1RBD group 3
7B9-9D11+2G1 [120]bispecific + antibody cocktail7B9-9D11RBD group 2/1BA.1 (1138 ng/mL)Exhibited complementary neutralization spectra.NA
2G1RBD
XMA01+XMA04+XMA09 [48]3-antibodies cocktailXMA01RBD class 1BA.1 (15.6 ng/mL)Exhibited synergistically enhanced neutralizing activity against Omicron.The XMA01/XMA04 dual-antibody cocktail exhibited synergistically enhanced in vivo protective efficacy (Syrian golden hamsters).
XMA04RBD class 2/3
XMA09RBD class 5
IMM-BCP-01 [114]3-antibodies cocktailIMM20184RBDBA.1 (62.89 nM)Exhibited synergistically enhanced neutralizing activity against early VOCs and Omicron BA.1/BA.2, and synergistically enhanced ADCC, ADCP, and CP.Exhibited synergistically enhanced in vivo prophylactic and therapeutic efficacy against Omicron BA.1 (Syrian golden hamsters).
IMM20190RBD
IMM20253RBD
B1-182.1+A19-46.1 [8]2-antibodies cocktailB1-182.1RBD class 1BA.1 (28.3 ng/mL)Exhibited synergistically enhanced neutralizing activity against Omicron.-
A19-46.1RBD class 2
H014+HB27+P17+FC05 [117]3/4-antibodies cocktailH014RBDNAExhibited synergistically enhanced spike binding.NA
HB27 alternateRBD
P17RBD
FC05NTD
WRAIR-2125+WRAIR-2039 [124]2-antibodies cocktailWRAIR-2125RBD class 1NAExhibited complementary neutralization spectra and increased the genetic barrier to viral escape.Showed significant in vivo prophylactic and therapeutic synergy (K18-hACE2 transgenic mice).
WRAIR-2039NTD antigenic supersite
EGH [115]3-antibodies cocktail13H7NTDBA.1, BA.2, BA.2.12.1, BA.5 (270–1091 ng/mL)Exhibited complementary neutralization spectra.NA
9G11RBD
3E2RBD
76E1+(ACE2/CB6/P2C-1F11/28-8L) [70]2-antibodies cocktail76E1FPNAExhibited synergistically enhanced neutralizing activity against SARS-CoV-2.NA
ACE2/CB6/P2C-1F11/28-8LRBD class 1
S2E12+C77G12 [73]2-antibodies cocktailC77G12/VN01H1FPNAExhibited synergistically enhanced neutralizing activity against SARS-CoV-2.NA
S2E12RBD
1249A8+1213H7 [83]2-antibodies cocktail1249A8SHBA.1 (25.8–1338 ng/mL)Exhibited synergistically enhanced neutralizing activity against Omicron.Showed in vivo prophylactic synergy in mice against Beta and Omicron, and therapeutic synergy in hamsters against Delta and SARS-CoV (K18 hACE2 transgenic mice, syrian golden hamster).
1213H7RBD
CV3-1+CV3-25 [123]2-antibodies cocktailCV3-1RBDNADid not exhibit synergistic enhancement of in vitro neutralizing activity or Fc effector functions.Did not exhibit synergistic enhancement in the prophylactic regimen (K18 hACE2 transgenic mice).
CV3-25SH
TATX-03b′ [126]4-antibodies cocktail23-H7RBDBA.1, BA.1.1, BA.2, BA.4/5, BA.2.12.1, BA.2.75 (20–8020 ng/mL)Exhibited synergistically enhanced neutralizing activity against Omicron BA.4/BA.5, and synergistically enhanced in vitro ADCC and ADCP.Exhibited synergistically enhanced in vivo viral clearance and alleviated lung pathology (Syrian golden hamster).
21-F2(N92Q)RBD
22-F7CT1
2-A6S2
SA55+SA58 [18]2-antibodies cocktailSA55RBDBA.1, BA.1.1, BA.2, BA.3, BA.2.13, BA.2.12.1, BA.4/5 (3.2–7.8 ng/mL)Exhibited synergistically enhanced neutralizing activity against Omicron.NA
SA58RBD
NA, not available.
Table 3. Representative of bi-/multi-specific antibodies against SARS-CoV-2.
Table 3. Representative of bi-/multi-specific antibodies against SARS-CoV-2.
NameFormatParent AntibodiesEpitopeNeutralizing Activity Against Omicron Sublineages (IC50)Enhanced Characteristics
FD01 [150](scFv)2-IgGGW01RBD class 4BA.1, BA.1.1, BA.2 (69.6–1285 ng/mL)Exhibited significantly greater binding activity, neutralizing activity, and mutation tolerance than parental antibodies and cocktails.
16L9RBM
G9 [127](scFv)2-IgGGW01RBMBA.1 (1257 ng/mL)Exhibited significantly greater neutralizing activity than parental antibodies.
REGN10989RBD, ACE2 non-competing
G7-Fc [145,154](scFv)2-IgGGW01RBD, ACE2 non-competingBA.1, BA.2, BA.2.12.1, BA.2.75, BL.1, BA.2.75.2, BA.2.75.4, BN.2.1, CA.1, BA.2.87.1, BA.2.86, BR.1, CH.1.1, XBB, XBB.1.5, XBB.1.16, XBB.1.16.1, BA.5, BR.1, BF.7, BA.4.6, BA.5.1.12, BA.5.6.2, BU.1, BQ.1.1, EG.5, JN.1, KP.2 (0.0191–4.3 nM)Exhibited significantly greater neutralizing activity and in vivo prophylactic and therapeutic efficacy than parental antibodies and cocktails.
7F3RBD class 2
Bi-Nab [136](scFv)2-IgG35B5RBD class 3BA.1, BA.2 (31.6–399.2 ng/mL)Bi-Nabs exhibited stronger binding and neutralizing activity against early VOCs than parental antibodies and cocktails, and markedly greater neutralizing activity against Omicron BA.1 and BA.2.
32C7RBD class 3
Bi-Nab [146](scFv)2-IgG35B5RBD class 3BA.1, BA.2 (0.15–0.67 nM)Exhibited greater RBD binding but lower S2 binding than parental antibodies, while showing broader neutralization breadth and greater neutralizing potency than parental antibodies and cocktails.
47D10S2
bn03 [134]tandem link (sdAb)2n3130vRBD, ACE2 non-competingBA.1 (100 ng/mL, Inferred from the neutralization curve)Exhibited significantly greater neutralizing activity than parental antibodies and cocktails.
n3113vRBD, ACE2 non-competing
bsAb15 [140]IgG-scFvB38RBD (around K417, N460)NAExhibited significantly greater neutralizing activity, mutation tolerance, and in vivo prophylactic and therapeutic efficacy than parental antibodies and cocktails.
H4RBD (around E484)
CoV-X2 [129]CrossMAbC121RBD (around E484)NAExhibited complementary neutralization spectra and significantly greater neutralizing activity than parental antibodies.
C135RBD (around R346)
14-H-06 [151]IgG-scFvCoV2-14RBD class 2BA.1 (1110 ng/mL)14-H-06 exhibited significantly greater binding activity, neutralizing potency, neutralization breadth, and in vivo therapeutic efficacy than parental antibody cocktails and 14crs-06.
CoV2-06RBD class 1
Bis4 [132]VH/Fab IgG KIHVH B01RBD B siteNAExhibited significantly greater neutralizing potency than parental antibodies and cocktails.
Fab D01RBD D site
CV1206_521_GS [149]DVD-IgCV1206RBD, ACE2 competingNAExhibited significantly greater neutralizing activity than parental antibodies and cocktails.
CV521NTD supersite
CoV2-biRN5 [58](scFv)2-IgGC1596NTD not supersiteBA.1, BA.2, BA.4/5, XBB.1.5, XBB.1.16, EG.5.1, HV.1, BA.2.86, JN.1 (1–5 ng/mL)CoV2-biRN5 exhibited markedly greater neutralizing activity against the tested viral strains than parental antibodies, cocktails, CrossMab, and DVD-Ig-format bispecific antibodies.
C952RBD class 3
KXD-BsAb02 [147]IgG-scFvKXD643RBD-8BA.1, BA.4/5, BA.2.75, BQ.1, XBB.1.5, EG.5.1, HK.3, BA.2.86, JN.1, KP.2, KP.3 (30–145 ng/mL)Exhibited significantly greater neutralizing activity than parental antibodies and cocktails.
KXD686NTD site iv
bsAb1 [137]IgG-scFvH4B6RBDBA.1, BA.2, BA.2.75, BA.2.76, BA.4/5, BA.4.6, BF.7, XBB.1.5, XBB.1.16, XBB.2.3, BA.2.86, JN.1 (2–17 ng/mL)Exhibited significantly greater binding activity, neutralization breadth, and neutralizing potency than parental antibodies and cocktails.
H4D12RBD
61.1/46.1–182.1 [148]CODV-IgA19-61.1RBD class 3 BA.1.1, BA.2, BA.2.12.1, BA.4/5 (26.2–1053 pM)Exhibited significantly greater neutralizing activity than parental antibodies and significantly greater mutation tolerance than parental antibodies and cocktails.
A19-46.1RBD class 2
B1-182.1RBD class 1
H11B11_m336 [141]IgG-scFvH11B11ACE2BA.2, BA.5, XBB.1.5 (251–424 ng/mL)Simultaneously neutralized SARS-CoV, SARS-CoV-2, and MERS-CoV, and exhibited significantly greater neutralizing activity than parental antibodies and cocktails.
m336MERS-CoV S
Bis3 [128]IgG-scFvCvMab-6RBDBA.1 (13.1 nM)Exhibited significantly greater neutralizing activity than parental antibodies and cocktails.
CvMab-62S2 (1123–1148)
COVA2-02+LY-CoV1404 [130]cFAECOVA2-02RBD unique epitopeBA.4/5, BQ.1.1, XBB.1 (2–13,600 ng/mL)Exhibited greater neutralizing activity than parental antibodies against some viruses, but variable performance relative to cocktails.
LY-CoV1404RBD class 3
BA7208+BA7125 [36]scFv/Fab IgG KIHBA7208RBD class 3BA.1, BA.2, BA.2.12.1, BA.2.13, BA.3, BA.4/5 (31.98–92.81 ng/mL)Exhibited complementary neutralizing activities and synergistically enhanced binding to the RBDs of Mu and Omicron BA.1.
BA7125RBD class 1
BI-2C5B [14]IgG-scFv6-2CRBD class 3BA.1, BA.2, BA.2.12.1, BA.2.75, BA.2.75.2, BN.1, BA.3, BA.4, BA.4.6, BA.5, BF.7, BQ.1, BQ.1.1, XD, XBB, XBB.1.5 (6–97 ng/mL)Exhibited neutralizing activity comparable to or greater than that of parental antibodies, effectively neutralized variants partially resistant to parental antibodies, and provided superior in vivo prophylactic protection at lower doses than parental antibodies and cocktails.
10-5BRBD class 1
5-HI [131]DVD-IgSCM 13–65S1BA.1, BA.2, BA.3, BA.5, BA.2.75, BQ.1, BF.7, XBB.1.5, EG.5.1, JN.1 (0.008–12.74 nM)Exhibited significantly greater binding activity, neutralization breadth, and neutralizing potency than parental antibodies and cocktails.
SCM 15–45S1
CoV-X4042 [66]CrossMabsd1.040SD1BA.1, BA.2, BA.2.75, BA.2.75.2, BA.4/5 (1000 ng/mL, inferred from the neutralization curve)Exhibited greater neutralizing activity than parental antibodies and cocktails.
rbd.042RBD
ShAb01H02K [143]VNAR-IgG KIHShAb01RBD class 4BA.1, BA.5 (391–524 ng/mL)Exhibited significantly greater binding activity, neutralization breadth, and neutralizing potency than parental antibodies.
ShAb02RBD class 3
7A9-19B8-S3_29 [135]tandem link (VHH)37A9RBD 353–364NAExhibited significantly greater neutralizing activity than parental antibodies and cocktails.
19B8NTD
S3_29apex of S2
TNᵀDNGR-1 [153](VHH)2-trimer-scFvERBDNATNᵀ and TNᵀDNGR-1 exhibited significantly greater neutralizing activity against Omicron BA.1 than TN; whereas parental antibodies (TN and TNᵀ) failed to protect against lethal infection, in vivo protection improved from ineffective to complete.
VRBD
7H11DNGR-1
Tripod-GS4r [152]sybody1-sybody2-trimerSb#15RBD, ACE2 competingNAExhibited significantly greater neutralizing activity than parental antibodies and cocktails.
Sb#68RBD, ACE2 non-competing
NB1A7+NB1B11 [144](VHH)2-IgG, etc.NB1A7RBD, ACE2 non-competingNAExhibited significantly greater neutralizing activity than parental antibodies.
NB1B11RBD, ACE2 competing
Nb1-Nb2-Fc [138](VHH)2-IgGNb1RBD, ACE2 non-competingBA.1, (0.0017 nM)Exhibited significantly greater neutralizing activity than parental antibodies and cocktails.
Nb2RBD, ACE2 competing
3F-1B-2A [139](VHH)3-IgG3FRBD, ACE2 non-competingNAExhibited significantly greater binding activity and neutralizing activity than parental antibodies and cocktails.
1BRBD, ACE2 competing
2ARBD, ACE2 competing
Tri-1 [133]KIH + CrossMab + IgG-scFvPW5-570RBMBA.1, XBB.1, EG.5.1, JN.1, JN.1.7, KP.2, KP.3.1.1 (0.034–19.08 nM)Tri-1/Tri-2 exhibited higher binding affinity, greater neutralizing potency, broader sarbecovirus coverage, and lower viral escape risk than parental mAbs and cocktails.
PW5-5RBD
PW5-535RBD nearby SD1
N-14-44-scFv [155]scFv-Fab-IgGP14-44RBD, noRBMBA.1 (2.02 ng/mL)N-14-44-scFv exhibits the highest neutralization potency, broadest activity against Omicron sublineages and superior in vivo protection compared with other bsAb formats, parental antibodies, and the cocktail.
P5-22RBM
NA, not available.
Table 4. Representative of other engineered antibodies against SARS-CoV-2.
Table 4. Representative of other engineered antibodies against SARS-CoV-2.
NameOriginal Antibody TypeTargetFormatEngineering AdvantagesNeutralizing Activity Against Omicron Sublineages (IC50)
W25-Fc [100]VHH from alpacasRBDhuman IgG FcW25-Fc exhibited greater neutralizing activity than W25, particularly by simultaneously engaging two up-state RBDs.BA.1, BA.2 (1.45–2.07 nM)
S2A9-hFc [109]VNAR from sharksS2human IgG1 FcS2A9-hFc exhibited greater neutralizing activity than its monomeric form due to bivalent effects.BA.1, BA.2, BA.4/5 (976–1854 nM)
MR14 [166]VHH from alpacasRBDhuIgG1, trivalent tandem nanobody, human IgMThese variants exhibited higher RBD affinity, greater neutralizing activity against Omicron sublineages, and improved in vivo protective efficacy; they also induced spike aggregation.BA.1, BA.2, BA.2.12.1, BA.2.75, BA.3, BA.4/5 (0.16–18.7 ng/mL)
79C11-Fc/79C11-Dimer/79C11-Trimer [108]VNAR from sharksHR1 (916–935)bivalent huIgG1 Fc/bivalent/trivalent tandem nanobodyMultivalent effects significantly enhanced binding affinity and neutralizing activity.BA.1, XBB.1.5, BA.2.86, JN.1 (0.011–0.075 μg/mL)
Bi-saRBD-1/Fc-saRBD-1 [168]VHH from alpacasRBD class 1(VHH)2, human IgG FcExhibited greater RBD affinity due to multivalent effects.NA
7F-7F/7F-Fc [169]VHH from llamasRBD class 4(VHH)2, human IgG FcExhibited greater neutralizing potency and broader neutralization breadth due to multivalent effects.BA.2, BA.5 (0.31–0.95 μM)
Nb19 trimer, etc. [170]VHH from alpacas/nanomiceRBD(VHH)3-human IgG1 FcMultimers exhibited greater binding avidity and neutralizing potency, compensating for mutation-induced affinity loss, and simultaneously cross-linked multiple spikes.NA
Nb4-16t [101]Synthetic nanobodyRBDtrivalent tandem nanobodyExhibited greater RBD affinity, enhanced neutralizing activity, broader neutralization breadth, and improved in vivo protective efficacy.BA.1.1, BA.2 (0.4–1.9 μg/mL)
DXP-604 mIgA1/dIgA1/sIgA1, etc. [157]human IgGRBD class 1monomeric/dimeric/secretory IgA1The longer hinge of IgA1 conferred greater flexibility, and the multivalent effect of dimeric IgA significantly enhanced neutralizing activity.BA.1, BA.2, BA.5 (0.03–3.43 nM)
H4-IgA1-m, H4-IgA1-d, etc. [161]human IgG1spikemonomeric/dimeric IgA1The long hinge region and multivalency of dimeric IgA enhanced viral spike cross-linking.NA
ZW2G10 (sIgA1) [160]human IgG1RBD, no competition with ACE2human IgG1/mIgA1/dIgA1/sIgA1/mIgA2/dIgA2/sIgA2The IgA form exhibited greater binding affinity, enhanced neutralizing activity, and improved in vivo protective efficacy due to its longer flexible hinge, multivalent binding, and mucosal adaptation.BA.2.75, BA.2.76, BA.4/5 (3.513–61.97 ng/mL)
REGN10933 IgG3 [164]human IgG1RBD class 1human IgG3The IgG3 form exhibited greater binding avidity and neutralizing potency owing to its long flexible hinge.BA.1 (0.34 nM)
IgM-14 [165]human IgGRBDhuman IgMIgM-14 exhibited greater neutralizing potency, broader neutralization breadth, and improved in vivo protective efficacy due to multivalent effects and mucosal adaptation.NA
MN235 [105]VHH from alpacasNTDhuman IgMMN235 exhibited enhanced neutralizing activity and superior in vivo protective efficacy owing to its ability to cross-link virions.BA.1, BA.1.1, BA.2, BA.4, BA.5, BF.7, XBB, EG.5.1 (0.012–0.941 μg/mL)
Nb6 tribody [167]VHH from camelidRBDtribodyTribody exhibited greater binding avidity and neutralizing potency due to multivalent effects.NA
mi3-1C4 [171]Mouse IgGRBD class 3mi3 nanoparticle by SpyTag/SpyCatcherExhibited greater binding affinity, enhanced neutralizing activity, broader neutralization breadth, and improved in vivo protective efficacy due to multivalent effects that promoted spike aggregation.BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.3.20, BA.2.75, BA.3, BA.4/5, BQ.1.1, BF.7, XBB, XBB.1.5, XBB.1.16, CH.1.1, EG.5, EG.5.1, BA.2.86, JN.1 (0.003–1.85 μg/mL)
XMA04-mi3 [172]Mouse IgGRBD class 2/3mi3 nanoparticle by SpyTag/SpyCatcherExhibited greater binding affinity, enhanced neutralizing activity, broader neutralization breadth, and enhanced ADCC due to multivalent effects that promoted spike aggregation.BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.4/5, XBB (2.6–6.3 ng/mL)
LS-B-B2 [173]VHH from alpacasRBDAsLS nanoparticle by SpyTag/SpyCatcherExhibited enhanced neutralizing activity and improved thermal stability due to multivalent effects and nanoparticulation.BA.1 (0.653 μg/mL)
SA55-IgA [162]Human IgGRBDHuman mono/dimer/secretory-IgA1IgA formats markedly enhanced or restored neutralization against IgG-resistant mutants.BA.1, BA.2, BA.4/5, BA.2.75, BF.7, CH.1.1, BQ.1.1, XBB.1, XBB.1.5, XBB.1.16, XBB.1.16.1, EG.5.1, BA.2.86, JN.1, JN.1 FLiRT, BA.2.87.1 (0.0009–0.1900 nM)
IgM-14 [182]Human IgGRBDHuman IgMIgM-14 exhibited greater neutralizing potency, broader neutralization breadth, and a higher resistance barrier than parental IgG-14.BA.1, BA.2, BA.3 (0.54–23.9 μg/mL)
2D4-IgA [183]VHH from alpacasRBDHuman IgA12D4-IgA exhibited greater and broader neutralizing activity, extended half-life, and effective mucosal delivery.BA.1, BA.4, BA.5, XBB (21.3–313.1 ng/mL)
Nb4×3 [184]VHH from dromedariesRBDTandem trimerNb4×3 exhibited greater neutralizing potency and broader activity against SARS-CoV-2 variants, especially escape sublineages.BA.1, BA.5, BQ.1.1 (0.05–4.32 nM)
NA, not available.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Jia, T.; Huang, Z.; Xia, N.; Yuan, Q. Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies. Viruses 2026, 18, 642. https://doi.org/10.3390/v18060642

AMA Style

Jia T, Huang Z, Xia N, Yuan Q. Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies. Viruses. 2026; 18(6):642. https://doi.org/10.3390/v18060642

Chicago/Turabian Style

Jia, Tianrong, Zehong Huang, Ningshao Xia, and Quan Yuan. 2026. "Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies" Viruses 18, no. 6: 642. https://doi.org/10.3390/v18060642

APA Style

Jia, T., Huang, Z., Xia, N., & Yuan, Q. (2026). Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies. Viruses, 18(6), 642. https://doi.org/10.3390/v18060642

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop